<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microb Pathog</journal-id><journal-id journal-id-type="iso-abbrev">Microb Pathog</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Microbial Pathogenesis</journal-title></journal-title-group><issn pub-type="ppub">0882-4010</issn><issn pub-type="epub">1096-1208</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7910145</article-id><article-id pub-id-type="pmcid-ver">PMC7910145.1</article-id><article-id pub-id-type="pmcaid">7910145</article-id><article-id pub-id-type="pmcaiid">7910145</article-id><article-id pub-id-type="pmid">33647446</article-id><article-id pub-id-type="doi">10.1016/j.micpath.2021.104809</article-id><article-id pub-id-type="pii">S0882-4010(21)00081-4</article-id><article-id pub-id-type="publisher-id">104809</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Sakr</surname><given-names initials="MM">Masarra M.</given-names></name></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Elsayed</surname><given-names initials="NS">Noha S.</given-names></name><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>El-Housseiny</surname><given-names initials="GS">Ghadir S.</given-names></name></contrib><aff id="aff1">Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Organization of African Unity St., 11566, Abbassia, Cairo, Egypt</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>27</day><month>2</month><year>2021</year></pub-date><volume>154</volume><issue-id pub-id-type="pmc-issue-id">376252</issue-id><fpage>104809</fpage><lpage>104809</lpage><history><date date-type="received"><day>3</day><month>11</month><year>2020</year></date><date date-type="rev-recd"><day>18</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>02</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-10 04:25:22.670"><day>10</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Amid the COVID-19 outbreak, several bioinformatic analyses have been conducted on SARS-CoV-2 virus genome. Numerous studies rushed to fill the gap about this novel virus. Comparison with other related sequences, structural predictions of the produced proteins, determination of variations in amino acid residues and depiction of possible drug and vaccine targets have been the focus of scientific research from the beginning of this year. In addition to discussing the viral taxonomy, clinical features, life cycle, and genome organization, this review will focus on the recent updates in genome and viral proteins characterization and potential therapeutic and vaccine candidates developed so far. Comparative studies with related genomes and proteins provide understanding for the viral molecular mechanisms and suggest targets for therapeutics and vaccinology trials to stop the escalation of this new virus. This pandemic, with its resulting social and economic afflictions, will definitely have significant marks on our lives in the following years.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Genome</kwd><kwd>Vaccine</kwd><kwd>Bioinformatics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0025">The speedy dissemination of COVID-19, which in less than 6 months has shifted from affecting some individuals in Wuhan (Hubei province, China) to greater than 7 million people and causing more than 400,000 deaths in nearly every country in the world [<xref rid="bib1" ref-type="bibr">1</xref>], has alarmed all public health systems and governments. The outbreak was believed to emerge from Wuhan City, Hubei province, in China at the end of 2019 and was allied to the Huanan Seafood Wholesale Market [<xref rid="bib2" ref-type="bibr">2</xref>]. Suspected patients were admitted to a selected hospital in Wuhan and by Jan 2, 2020, a total of 41 patients had been recognized as having laboratory-confirmed COVID infection. During the Spring Festival travel season in January 2020, the virus extended to other areas in China, and was subsequently transmitted to other countries through international travelers [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0030">Worobey et al. (2020) explained the establishment of the earliest SARS-CoV-2 transmission networks in Europe and North America. Their findings propose that the virus was disallowed to take hold in USA and Germany early due to the swift and early interferences. Introductions of the virus from China to Italy and Washington later initiated the earliest continuous transmission networks [<xref rid="bib4" ref-type="bibr">4</xref>].</p><p id="p0035">However, a recent study unexpectedly detected SARS-CoV-2 antibodies in the pre-pandemic period in Italy. Beginning from September 2019, SARS-CoV-2 RBD-specific antibodies were detected in 11.6% of people in Italy. This study proves that SARS-CoV-2 circulated between asymptomatic persons in Italy a few months before the first patient was recognized. Detecting SARS-CoV-2 antibodies in asymptomatic people prior to the outbreak in Italy may restructure the pandemic history [<xref rid="bib5" ref-type="bibr">5</xref>].</p><p id="p0040">Due to a marked increase in the infections in several countries, the virus outbreak was declared to be a Public Health Emergency of International Concern by the World Health Organization (WHO) on January 30, 2020 [<xref rid="bib6" ref-type="bibr">6</xref>]. On the 11th of February 2020, the International Committee on Taxonomy of Viruses called the virus &#8220;severe acute respiratory syndrome coronavirus-2&#8221; (SARS-CoV-2) based on the phylogenetic analysis [<xref rid="bib7" ref-type="bibr">7</xref>]. That day, the WHO also named the illness resulting from this virus &#8220;Coronavirus Disease 2019&#8221; (COVID-19) [<xref rid="bib8" ref-type="bibr">8</xref>]. Due to the very quick rise in the total affected cases and countries, the WHO announced SARS-CoV-2 a pandemic on March 11, 2020 [<xref rid="bib9" ref-type="bibr">9</xref>]. As of December 27th, 2020, over 79.2 million cases and over 1.7 million deaths have been reported [<xref rid="bib10" ref-type="bibr">10</xref>].</p><sec id="sec1.1"><label>1.1</label><title>Virus/disease characterization</title><sec id="sec1.1.1"><label>1.1.1</label><title>Taxonomy and general characters</title><p id="p0045">Coronaviruses form part of the subfamily <italic toggle="yes">Orthocoronavirinae,</italic> family <italic toggle="yes">Coronaviridae</italic>, suborder <italic toggle="yes">Coronavirinae</italic>, order <italic toggle="yes">Nidovirales</italic> [<xref rid="bib11" ref-type="bibr">11</xref>]. This subfamily is classified into 4 genera &#8211; <italic toggle="yes">alpha</italic>, <italic toggle="yes">beta, gamma</italic> and <italic toggle="yes">delta coronavirus</italic>. Until this year, only 6 coronaviruses are proven to evoke infections in humans. Four of them are endemic in humans, and cause only mild upper respiratory symptoms, known as human coronaviruses (HCoV) 229E, NL63 (both from genera <italic toggle="yes">alphacoronavirus</italic>), OC43 and HKU1 (both from genera <italic toggle="yes">betacoronavirus</italic>) [<xref rid="bib12" ref-type="bibr">12</xref>]. The remaining two, both from genera <italic toggle="yes">betacoronavirus</italic>, are epidemic human coronaviruses and cause severe lower respiratory symptoms: Middle East respiratory syndrome coronavirus (MERS-CoV), which appeared in 2012 in Saudi Arabia [<xref rid="bib13" ref-type="bibr">13</xref>], and severe acute respiratory syndrome coronavirus (SARS-CoV), which originated in China in 2002&#8211;2003 [<xref rid="bib14" ref-type="bibr">14</xref>]. <italic toggle="yes">Gamma</italic> and <italic toggle="yes">deltacoronavirus</italic>, on the other hand, include several avian coronaviruses [<xref rid="bib12" ref-type="bibr">12</xref>]. SARS-CoV-2, as revealed by sequence analysis, has an archetypal genome structure of coronaviruses, specifically <italic toggle="yes">Betacoronavirus</italic>, subgenus <italic toggle="yes">Sarbecovirus</italic>. It is regarded as the seventh coronavirus that infects humans till now [<xref rid="bib15" ref-type="bibr">15</xref>].</p><p id="p0050">Coronaviruses are pervasive pathogens in nature, leading to gastrointestinal or respiratory infections and sometimes affecting vital systems in humans and animals. They are inactivated by UV rays, high temperatures, lipid solvents like ether, 75% ethanol, chlorine-containing disinfectants, and chloroform [<xref rid="bib16" ref-type="bibr">16</xref>].</p></sec><sec id="sec1.1.2"><label>1.1.2</label><title>Transmission</title><p id="p0055">When COVID-19 first started in China, human to human transmission was doubtful, up till the appearance of patients not connected to the seafood market. As outbreaks emerged all around the world, human-to-human transmission became obvious [<xref rid="bib17" ref-type="bibr">17</xref>].</p><p id="p0060">SARS-CoV-2 transmission, like other respiratory viruses, occurs via respiratory droplets, indirect or direct contacts [<xref rid="bib18" ref-type="bibr">18</xref>]. However, its transmission rate is greater than SARS-CoV and MERS-CoV. The infection risk rises the longer and nearer a person is to an infected person, and unventilated enclosed packed places are more hazardous than the open air. Some reports have proposed a relation between the quantity of virus exposure and the harshness of disease, though this relation remains questionable, as the severity of disease is more likely to depend on the person's immunity [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0065">Fomite transmission's role is not yet completely known. Accurate information on the environmental stability of SARS-CoV-2 is needed to verify the risks of fomite transmission from contaminated surfaces. SARS-CoV-2 was described to last on numerous surfaces including stainless steel, plastic, glass, and cardboard for a minimum of several hours [<xref rid="bib20" ref-type="bibr">20</xref>]. In September 2020, studies suggested that a protein-rich medium like airway secretions could protect the virus and may augment its persistence and spread by contaminated fomites. Consequently, virus contaminated fomites may have a substantial role in the indirect transmission of COVID-19. This conclusion verifies surface cleaning as it may have a vital role in stopping SARS-CoV-2 transmission [<xref rid="bib21" ref-type="bibr">21</xref>]. Moreover, Riddell et al. (2020) determined the existence rates of SARS-CoV-2 at diverse temperatures. Infectious virus was isolated from glass, stainless steel and paper for up to 28 days at 20&#160;&#176;C. On the contrary, it lasted fewer than 24&#160;h&#160;at 40&#160;&#176;C on some surfaces [<xref rid="bib22" ref-type="bibr">22</xref>].</p><p id="p0070">Alternatively, a recent study suggested that environmental contamination leading to SARS-CoV-2 transmission is not likely to happen, provided that standard cleaning precautions are imposed. Hence the chance of transmission through inanimate surfaces is less common than formerly recognized [<xref rid="bib23" ref-type="bibr">23</xref>].</p><p id="p0075">Airborne transmission might also probably occur in specific settings that generate high concentrations of aerosols in a closed environment, but this still has to be evidenced scientifically [<xref rid="bib18" ref-type="bibr">18</xref>]. Whole blood and urine of COVID-19 patients were found to contain SARS-CoV-2 RNA, which suggests that transmission through these routes is likely [<xref rid="bib24" ref-type="bibr">24</xref>]. Moreover, studies proved that stool samples also contained SARS-CoV-2 prior to and after treatment, indicating that the fecal-route transmission of SARS-CoV-2 should not be neglected [<xref rid="bib25" ref-type="bibr">25</xref>].</p><p id="p0080">Concerning the vertical spread of COVID-19, an early study suggested that no vertical transmission of SARS-CoV-2 occurred throughout 3rd trimester of pregnancy, where no virus was detected in the newborns of 9 infected women [<xref rid="bib26" ref-type="bibr">26</xref>]. However, the small number of cases analysed in the study makes further studies to prove this essential. Moreover, 2 of 6 neonates of COVID-19 infected women had high IgG and IgM antibodies to SARS-CoV-2 in another study [<xref rid="bib27" ref-type="bibr">27</xref>]. In July 2020, a meta-analysis of SARS-CoV-2 infection and pregnancy was performed and showed that vertical transmission of the virus is possible, though in a small percentage of cases [<xref rid="bib28" ref-type="bibr">28</xref>].</p></sec><sec id="sec1.1.3"><label>1.1.3</label><title>Clinical features of COVID-19</title><p id="p0085">The predicted incubation period of SARS-CoV-2 is 2&#8211;14 days, with the median incubation period being 4 days [<xref rid="bib29" ref-type="bibr">29</xref>]. The illness starts with flu-like symptoms that most commonly consist of fever, fatigue and dry cough. Other symptoms include sore throat, shortness of breath, chest tightness and muscle pain. Non respiratory manifestations including palpitation, diarrhea, or headache sometimes precede respiratory symptoms. Patients may have runny nose, nausea and vomiting [<xref rid="bib30" ref-type="bibr">30</xref>]. SARS-CoV-2 may cause gastrointestinal symptoms due to a direct damage to the intestine [<xref rid="bib29" ref-type="bibr">29</xref>].</p><p id="p0090">In addition to the gastrointestinal symptoms, several retrospectives studies reported that patients with COVID-19 experienced hypogeusia and hyposmia which may be due to the swelling of the nasal mucosa [<xref rid="bib31" ref-type="bibr">31</xref>]. Olfactory and gustatory dysfunctions are currently being listed to be from the initial warning signs and for improved case detection.</p><p id="p0095">COVID-19 may result in complications leading to severe infections. Serious cases frequently suffer dyspnea and/or hypoxemia 7 days following the beginning of the illness, which can swiftly progress to Acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, coagulopathy and multiple organ failure. about 80% of patients have leukopenia, and 72.3% have lymphocytopenia and elevated C reactive protein (CRP) levels [<xref rid="bib32" ref-type="bibr">32</xref>]. Most chest computed tomography (CT) images of lungs show lesions (sometimes dense) in numerous lung lobes. Ground-glass opacity together with consolidation shadows have been reported [<xref rid="bib33" ref-type="bibr">33</xref>]. However, a wide range of severity patterns is exhibited during the course of the disease. Dyspnea occurs within 8 days after the disease onset in a few patients, whilst it may not happen in other patients [<xref rid="bib34" ref-type="bibr">34</xref>].</p><p id="p0100">Patients with mild disease can recover after 2 weeks, while severe cases last nearly 3&#8211;6 weeks, with death occurring from 2 to 8 weeks [<xref rid="bib35" ref-type="bibr">35</xref>]. Current cases prove a good prognosis for that the majority of patients, but not the old-aged and those with chronic illnesses or malignancy [<xref rid="bib16" ref-type="bibr">16</xref>]. Moreover, although mild symptoms have been reported in children, ethnicity and previous comorbidities might be independent risk factors for critical illness [<xref rid="bib36" ref-type="bibr">36</xref>]. It must be noted that asymptomatic persons may also be infected with SARS-CoV-2 [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib37" ref-type="bibr">37</xref>] which allows a more effective spread of the virus from one person to another.</p></sec><sec id="sec1.1.4"><label>1.1.4</label><title>Structure of SARS-COV-2</title><p id="p0105">Coronaviruses are enveloped, single-stranded RNA viruses ranging from 80 to 220&#160;nm in diameter. The envelop possesses crown-like spikes (20-nm in length) similar to the sun's corona under electron microscopy, thus its name coronavirus (<xref rid="fig1" ref-type="fig">Fig. 1</xref>
A) [<xref rid="bib12" ref-type="bibr">12</xref>]. They also bear the largest genome among the presently known RNA viruses, ranging between 27 and 34&#160;kB [<xref rid="bib38" ref-type="bibr">38</xref>]. Electron micrographs of the novel SARS-CoV-2 particles were mostly spherical with a diameter of 60&#8211;140&#160;nm, and spikes about 9&#8211;12&#160;nm in length [<xref rid="bib15" ref-type="bibr">15</xref>].<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Severe Acute Respiratory Syndrome Coronavirus 2 structure [<xref rid="bib12" ref-type="bibr">12</xref>].</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p><p id="p0110">Coronaviruses have 4 main structural proteins: the nucleocapsid (N), spike (S), envelope (E) and membrane (M) structural proteins. The viral envelope is formed of the latter three structural proteins [<xref rid="bib39" ref-type="bibr">39</xref>].</p><p id="p0115">The S glycoprotein is a transmembrane protein (molecular weight 150&#160;kDa) projecting from the surface of the virus. S protein monomers assemble into homotrimers and aid in binding of the virus to host cells ACE2 receptor. To further understand the SARS-CoV-2 S protein, its structure was determined by cryo&#8211;electron microscopy [<xref rid="bib40" ref-type="bibr">40</xref>]. This glycoprotein is split into 2 sub units, S1 and S2, by a host cell protease. The S1 subunit, defined by the C-terminal domain (CTD) holding the receptor binding domain (RBD) and the N-terminal domain (NTD), determines the host virus range and cellular tropism. S2 subunit, containing an internal membrane fusion peptide (FP), two 7-peptide repeats (HR), a membrane proximal external region (MPER), and a trans-membrane domain (TM), is involved in membrane fusion [<xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>].</p><p id="p0120">The most abundant surface structural protein, the M glycoprotein (molecular weight 25&#160;kDa) is concerned in virus assembly [<xref rid="bib44" ref-type="bibr">44</xref>]. The E protein, the smallest protein in SARS-CoV-2, is concerned with the production and maturation of this virus [<xref rid="bib45" ref-type="bibr">45</xref>]. The N protein is bound to the nucleic acid of the virus, and consequently, is involved in viral genome and replication cycle related processes [<xref rid="bib45" ref-type="bibr">45</xref>].</p></sec><sec id="sec1.1.5"><label>1.1.5</label><title>Genome Organization and Characterization</title><p id="p0125">Laboratories around the world have been working on sequencing SARS-CoV-2 genome in an attempt to provide better understanding of the virus structure, mechanisms, and possible drug targets. By the 1st of June, a total of 4988 sequences have been submitted to the NCBI GenBank database including the reference sequence for SARS-CoV-2 genome (NCBI RefSeq NC_045,512). Homology analysis of the submitted sequences were conducted in several studies and revealed that the overall homology among the full&#8208;length SARS-CoV-2 genomic sequences was more than 99% [<xref rid="bib46" ref-type="bibr">46</xref>]. SARS-CoV-2 is a positive-sense single stranded RNA virus. Their genomes typically begin with a 5&#8242;-methylguanosine cap (also referred to as 5&#8242;UTR) and end with a 3&#8242;-poly-A tail (3&#8242;UTR). The genome of SARS-CoV-2 is approximately 29.8&#160;Kb in length with G&#160;+&#160;C content of 38% and is annotated to possess 11 ORFs encoding at least 26 proteins [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. These proteins play a crucial role in viral survival and virulence. More than two thirds of the genome consist of ORF1a and ORF1b containing replication and transcription related genes which encode 16 non-structural proteins (nsps). The rest of the genome encodes the 4 previously mentioned structural proteins in addition to other 6 accessory proteins encoded by ORF3a, ORF6, ORF7a, ORF7b, ORF8 and ORF10 genes (<xref rid="fig2" ref-type="fig">Fig. 2</xref>
). Being a positive sense RNA virus, the viral genome is ready to be translated into proteins once entry into the host cell is achieved and the genomic material released. The next part will discuss the different ORFs of the viral genome in order, the produced proteins, their functions, and homology studies with relevant proteins shedding light on the most important outcomes of recent studies on SARS-CoV-2.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Schematic representation of SARS-CoV-2 genome organization. The genome consists of a single long open reading frame with two flanking untranslated regions (UTRs). The genome is arranged in the order of 5&#8242; UTR (265 nucleotides)-<italic toggle="yes">orf</italic>1ab (the replicase gene)-orfS- orf3a-orfE-orfM- orf 6- orf 7a-orf 7b- orf8-orf N-orf 10&#8211;3&#8242;UTR (358 nucleotides). ORF1ab encodes for two large polyproteins, pp1a and pp1ab. Expression of these two polyproteins is achieved by ribosomal frame shifting. These two polyproteins are cleaved into 16 non-structural proteins by the action of two proteases, PLpro encoded by nsp3 and Mpro encoded by nsp5. The rest of the genome encodes for 4 structural proteins; Spike protein (S), Envelope protein (E), Membrane protein (M), nucleocapsid protein (N) in addition to six accessory proteins (coloured white); 3a, 6, 7a, 7b, 8 and 10. The main domains of the four structural proteins are shown. The prefusion structure of S protein is displayed showing the RBD highlighted in green, adopted from Wrapp et al. [<xref rid="bib40" ref-type="bibr">40</xref>], and the Homopentamer of E pentameric protein which modulates ion channel activity of the E protein is also illustrated, adopted from Gupta et al. [<xref rid="bib49" ref-type="bibr">49</xref>].</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p></sec><sec id="sec1.1.6"><label>1.1.6</label><title>ORF1ab</title><p id="p0130">The ORF1ab encodes two large non-structural polyproteins upon translation. Translation takes place by ribosomal frame shifting producing the two large replicase polyproteins pp1ab and pp1a<bold>.</bold> These polyproteins are then processed into sixteen nsps. Cleavage of the polyproteins takes place by the action of two proteases; papain-like protease (PLpro) which is encoded by nsp3 and a serine type Mpro which is the main protease and also referred to as 3CLpro (chymotrypsin-like protease) encoded by nsp5 [<xref rid="bib50" ref-type="bibr">50</xref>]. These nsps play a vital role, whose functions could be predicted from the studies conducted on SARS-CoV-1 due to the homology between the sequences of SARS-CoV-1 and SARS-CoV-2 (<xref rid="tbl1" ref-type="table">Table 1</xref>
). Several studies focused on comparing sequences of nsps of SARS-CoV-2 to homologous proteins in other related coronaviruses. A study conducted homology modelling to compare between nsp2 and nsp3 of SARS-CoV-2, SARS-CoV-1 and bat SARS&#8208;like CoV. It was observed that the amino acid in position 501 (321 of the nsp2 protein) was a polar amino acid in SARS-CoV-2 conferring a higher stability to the protein whereas the corresponding site in Bat SARS-like CoV has a non-polar amino acid. The same study reported that the position 723 in the SARS-CoV-2 (543 in nsp3) has a serine instead of the glycine residue present in bat SARS-like CoV and SARS-CoV-1. In the amino acid position 1010, the SARS-CoV-2 has a proline residue, the bat SARS&#8208;like coronavirus has a histidine residue and the SARS-CoV-1 has an isoleucine residue. The study assumes that the stabilizing mutation in the nsp2 could account for SARS-CoV-2 highly contagious ability, while the destabilizing mutation in nsp3 could suggest a mechanism that differentiates COVID&#8208;2019 from SARS [<xref rid="bib51" ref-type="bibr">51</xref>]. Khailany et al. analysed 95 SARS-CoV-2 complete genome sequences and reported that nsp3 displayed more variants than other nsps [<xref rid="bib52" ref-type="bibr">52</xref>]. A huge comparative study analysed the genomes of 10,022 SARS-CoV-2 sequences and also noted that nsp3 had the largest number of missense variants among nsps [<xref rid="bib53" ref-type="bibr">53</xref>]. The same study reported mutations in nsp12 (the RNA-dependant RNA polymerase) and deletions in nsp14 (the 3&#8242;-5&#8242; exonuclease). A recent study on molecular characterization of a SARS-CoV-2 in a COVID-19 cluster in France reported a deletion of an amino acid in nsp2 (Asp 268 Del) when compared to the sequence of the reference strain (isolate Wuhan-Hu-1, EPI_ISL_402,125). The study suggested the spread of this deletion in the SARS-CoV-2 clusters in Europe and mentioned that the impact of this deletion on the transmission and pathogenicity of the virus had be evaluated [<xref rid="bib54" ref-type="bibr">54</xref>].<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p><bold>List of non-structural proteins (nsps) of SARS-CoV-2, their amino acid lengths, and functions</bold>.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Non- structural protein nsp</th><th colspan="1" rowspan="1">Amino acid length and position</th><th colspan="1" rowspan="1">Function</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">nsp1</td><td align="left" colspan="1" rowspan="1">180 aa (residues 1&#8211;180)</td><td align="left" colspan="1" rowspan="1">Suppresses host innate immune functions. It supresses type I IFN expression in infected cells. This antagonism takes place by degradation of host mRNA and inactivation of host translational machinery.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib55" ref-type="bibr">[55]</xref>, <xref rid="bib56" ref-type="bibr">[56]</xref>, <xref rid="bib57" ref-type="bibr">[57]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp2</td><td align="left" colspan="1" rowspan="1">638 aa (residues 181&#8211;818)</td><td align="left" colspan="1" rowspan="1">Interacts with host factors prohibitin 1 and 2 which are involved in many cellular processes.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp3</td><td align="left" colspan="1" rowspan="1">1945 aa (residues A819-G2763)</td><td align="left" colspan="1" rowspan="1">It is the largest protein in the coronavirus genome. It is a large transmembrane protein, a papain-like protease (PLpro) responsible for the processing of viral polyproteins encoded from the genomic RNA to individual protein components. It was also shown to antagonize host innate immunity.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib59" ref-type="bibr">59</xref>,<xref rid="bib60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp4</td><td align="left" colspan="1" rowspan="1">500 aa (residues K2764 &#8211; Q3263)</td><td align="left" colspan="1" rowspan="1">A multipass membrane protein responsible for membrane rearrangement. It interacts with nsp3 and 6 to form double membrane vesicles (DMV). This interaction is crucial for viral replication complex formation.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib59" ref-type="bibr">59</xref>,<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp5</td><td align="left" colspan="1" rowspan="1">306 aa (residues S3264 &#8211; Q3569)</td><td align="left" colspan="1" rowspan="1">Mpro, chymotrypsin-like protease (3CLpro), the viral main protease considered the key enzyme which digests the viral polyprotein at no less than 11 conserved sites including its autolytic cleavage from polyproteins pp1a and pp1ab.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib59" ref-type="bibr">59</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp6</td><td align="left" colspan="1" rowspan="1">290 aa (residues S3570-Q3859</td><td align="left" colspan="1" rowspan="1">A transmembrane scaffold protein that forms a complex with nsp3 and nsp4 (DMV formation)</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp7</td><td align="left" colspan="1" rowspan="1">83 aa (residues S3860 &#8211; Q3942)</td><td align="left" colspan="1" rowspan="1">A cofactor that binds to nsp8 forming hexadecameric complex and acts as processivity clamp for RNA polymerase and primase</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib64" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp8</td><td align="left" colspan="1" rowspan="1">198 aa (residues A3943 &#8211; Q4140)</td><td align="left" colspan="1" rowspan="1">A cofactor that binds to nsp7 forming hexadecameric complex and acts as processivity clamp for RNA polymerase and primase</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib64" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp9</td><td align="left" colspan="1" rowspan="1">113 aa (residues N4141 &#8211; Q4253)</td><td align="left" colspan="1" rowspan="1">A ss-RNA binding protein. Putatively stabilizes nascent nucleic acid during replication or transcription protecting it from nucleases.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp 10</td><td align="left" colspan="1" rowspan="1">139 aa (residues A4254 &#8211; Q4392)</td><td align="left" colspan="1" rowspan="1">A small protein believed to act as a multifunctional cofactor. In replication it interacts with nsp14 involved in replication fidelity and also interacts with nsp16.<break/>It interacts with nsp14 and 16 stimulating exonuclease and O-methyl transferase activity.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp 11</td><td align="left" colspan="1" rowspan="1">11-23 aa (residues S4393 &#8211; V4405)</td><td align="left" colspan="1" rowspan="1">It is a short peptide at the end of ORF1a and represents the frameshift boundary. It is a pp1a cleavage product of an unknown function.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp12</td><td align="left" colspan="1" rowspan="1">932 aa (residues S4393 &#8211; Q5324)</td><td align="left" colspan="1" rowspan="1">It is the RNA-dependant RNA polymerase (RdRp) responsible for both replication and transcription of the viral genome. Formation of new viral RNA mediated by RdRp is believed to be the key step in viral life cycle.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp 13</td><td align="left" colspan="1" rowspan="1">601 aa (residues A5325 &#8211; Q5925)</td><td align="left" colspan="1" rowspan="1">A helicase composed of an N-terminal metal binding domain and a helicase conserved domain. It plays an important role in viral replication by having the ability to unwind duplex RNA and DNA.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp14</td><td align="left" colspan="1" rowspan="1">527 aa (residues A5926 &#8211; Q6452</td><td align="left" colspan="1" rowspan="1">It has 3&#8242;-5&#8242; exoribonuclease activity which is important in proof reading during viral RNA replication and has N-7-Guanine methyl transferase activity which is involved in mRNA capping.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp15</td><td align="left" colspan="1" rowspan="1">346 aa (residues S6453 &#8211; Q6798)</td><td align="left" colspan="1" rowspan="1">It is a poly(U)-speci&#64257;c endoribonuclease enzyme which cleaves RNA at the 3&#8242; end of uridylates. Loss of nsp15 was found to affect viral replication and virulence.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">nsp16</td><td align="left" colspan="1" rowspan="1">298 aa (residues S6799 &#8211; N7096</td><td align="left" colspan="1" rowspan="1">It has 2-O methyl transferase activity which is essential for capping of viral mRNA to escape host detection.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="sec1.1.7"><label>1.1.7</label><title>ORF 2-10</title><p id="p0135">This part is made of 9 sub-genomic mRNA sequences which code for the structural proteins (Spike, Envelope, Membrane and Nucleocapsid) in addition to 6 accessory proteins (3a, 6, 7a, 7b, 8 and 10). Some of these proteins undergo glycosylation in the Golgi apparatus forming glycoproteins.</p><p id="p0140">ORF S: has a length of 3822 nucleotides [<xref rid="bib46" ref-type="bibr">46</xref>], and codes for the spike surface glycoprotein which is formed of S1 and S2 subunits as mentioned previously. Accordingly, several studies conducted sequence alignments of this protein with those of related coronaviruses to detect amino acid conservation and variation. A study by Chan et al. observed very high homology (99%) between the S2 subunit of SARS-CoV-2, the two bat SARS-like CoVs and human SARS-CoV-1. This suggests that antiviral peptides which are active against S2 could be used against SARS-CoV-2. Subunit S1 was found to share 70% identity with bat SARs-like CoVs and human SARS CoV-1 [<xref rid="bib47" ref-type="bibr">47</xref>]. However, although the core domain of RBD in S1 was found to be highly conserved, the external subdomain which is responsible for the interaction with the host receptor was found to share only 40% amino acid identity with other SARS-related CoVs [<xref rid="bib47" ref-type="bibr">47</xref>]. Another study assessing the variants in S protein revealed 427 non-synonymous variants many of which are located within RBD and B-cell epitopes [<xref rid="bib53" ref-type="bibr">53</xref>]. Sequence alignment revealed difference in five critical amino acids in RBD of S1 subunit between SARS-CoV-2 and SARS-CoV and 3D structural analysis showed that the spike protein of SARS-CoV-2 has a higher affinity to the receptor ACE2 than S protein of SARS-CoV-1 [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib68" ref-type="bibr">68</xref>].</p><p id="p0145">In November 2020, the WHO published an alert reporting a mink-associated variant strain of SARS-CoV-2 in Denmark (referred to as the cluster 5 variant) [<xref rid="bib69" ref-type="bibr">69</xref>]. This variant strain displayed several amino acid changes in the spike protein [<xref rid="bib70" ref-type="bibr">70</xref>]. A more recent alert was published reporting a variant strain in UK which displayed a range of 14&#8211;17 mutations, the most significant of which is an N501Y mutation in the spike protein resulting in alteration in the key residues in the RBD [<xref rid="bib71" ref-type="bibr">71</xref>].</p><p id="p0150">In a research assessing the effect of D614G spike mutation on the pathogenicity and transmissibility of SARS-CoV-2, where glycine replaces aspartic acid at position 614 of spike protein, 614G was reported to have become more prevalent than 614D though initially 614D was the more prevailing variant strain suggesting a selective advantage for 614G. The variant 614G was found to be associated with higher viral loads in younger patients. However, no increase in the severity or mortality of COVID-19 patients was observed [<xref rid="bib72" ref-type="bibr">72</xref>].</p><p id="p0155">ORF 3a: is 828 nucleotides in length and codes for 3a accessory protein [<xref rid="bib46" ref-type="bibr">46</xref>]. It is also worth mentioning that some of the early studies on SARS-CoV-2 reported the presence of accessory protein 3b [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. One study described it as a short novel putative protein with four helices [<xref rid="bib47" ref-type="bibr">47</xref>].</p><p id="p0160">ORF E: formed of 228 nucleotides in length [<xref rid="bib46" ref-type="bibr">46</xref>]. It codes for the envelope protein which is conserved across &#946;-coronaviruses [<xref rid="bib73" ref-type="bibr">73</xref>]. Envelope protein is an integral membrane protein that consists of N-terminal, transmembrane and C-terminal domains [<xref rid="bib45" ref-type="bibr">45</xref>]. Previous studies showed that E proteins oligomerize to form ion channels which is important for pathogenesis. Despite being a minor component of the virus membrane, it plays a key role in viral pathogenesis and induction of overexpression of inflammatory cytokines. It also participates in viral assembly and release of new viral particles [<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib74" ref-type="bibr">74</xref>]. It is also worth mentioning that a study by Gupta et al. reported that &#945;-helix and loops present in the E protein of SARS-CoV-2 experience random movement. This happens under optimal conditions modulating the ion channel activity of E protein which is associated with pathogenesis [<xref rid="bib49" ref-type="bibr">49</xref>].</p><p id="p0165">Comparison between the SARS-CoV-2 E protein with homologous proteins from closely related viruses showed E protein to be highly conserved with only 3 variants found across 797 studied genomes. A distinguishing feature of SARS-CoV-2 E protein was observed which is the presence of Arg at position 69 instead of Glu, Gln, Asp in other homologous SARS-CoV E proteins followed by a deletion in position 70 instead of Gly or Cys in the other proteins. The study with this finding hypothesized these changes may have a significant effect on protein-protein interaction [<xref rid="bib73" ref-type="bibr">73</xref>].</p><p id="p0170">ORF M: consists of 669 nucleotides [<xref rid="bib46" ref-type="bibr">46</xref>]. It codes for the membrane protein (M) which is the most abundant structural protein and constitutes the majority of the viral membrane. It is thought to play a central role in viral assembly and budding through interaction with other structural proteins, mainly E and N proteins [<xref rid="bib75" ref-type="bibr">75</xref>]. Like the E protein, M protein consists of three domains, the N-terminal domain, trans-membrane helices and the C-domain. A study on SARS-CoV-2 E and M proteins revealed that M protein shared 98% identity with sequences from Bat and Pangolin isolates. Among 797 studied genomes, M protein displayed 7 variants. The study reported a unique feature in M protein of the current SARS-CoV-2, a serine residue at position 4 present in all the M variants that the study concluded. In homologous proteins, the corresponding position to this Ser was either a deletion or an Asp. The study assumed that since this mutation from relevant Coronaviruses lies in the N-terminus region which lies outside of the virus particle, it may play an important role in virus-host interaction [<xref rid="bib73" ref-type="bibr">73</xref>].</p><p id="p0175">ORF 6: formed of 186 nucleotides and codes for Orf6 accessory protein which is formed of 61 amino acids [<xref rid="bib46" ref-type="bibr">46</xref>].</p><p id="p0180">ORF 7a and ORF 7b: formed of 366 and 132 nucleotides, respectively [<xref rid="bib46" ref-type="bibr">46</xref>]. Produced protein 7a is believed to play an important part in viral pathogenesis where it functions to induce apoptosis of the infected cell and arrest the cell cycle in addition to promoting the production of pro-inflammatory cytokines [<xref rid="bib45" ref-type="bibr">45</xref>]. Amino acid identity between 7a and 7b proteins of SARS-CoV-2 revealed more sequence identity with Bat SARS-like CoV than human SARS-CoV-1 [<xref rid="bib48" ref-type="bibr">48</xref>].</p><p id="p0185">ORF8: This gene is 366 nucleotides in length [<xref rid="bib46" ref-type="bibr">46</xref>] and codes for a 121 amino acid protein. Orf8 of SARS-CoV-2 is different from that of other related coronaviruses. It lacks a known useful aggregation motif (VLVVL) which is found in SARS-CoV-1 orf8b and was reported to trigger intracellular stress pathways and to activate inflammasomes [<xref rid="bib76" ref-type="bibr">76</xref>]. Instead, secondary structure prediction of this novel orf8 short protein revealed it is a protein with an alpha-helix and a beta-sheet that contains six strands [<xref rid="bib47" ref-type="bibr">47</xref>]. Multiple sequence alignment showed the protein sequence of SARS-CoV-2 Orf8 shared very low similarity with that of SARS-CoV-1 [<xref rid="bib48" ref-type="bibr">48</xref>,<xref rid="bib68" ref-type="bibr">68</xref>] It belongs to the group that includes the closest genome sequences of bat SARS like CoVs ZXC21 and ZC45 whereas it is distant from the orf8 of human SARS-CoV-1 [<xref rid="bib47" ref-type="bibr">47</xref>] Several studies believe examining the biological function of this particular protein (orf8) will be critical in understanding the pathogenesis of SARS-CoV-2 [<xref rid="bib52" ref-type="bibr">52</xref>].</p><p id="p0190">ORF N: it is 1260 nucleotides in length. It codes for the N protein which is a highly phosphorylated protein, 419 amino acids in length and constitutes the only protein in the nucleocapsid [<xref rid="bib46" ref-type="bibr">46</xref>]. It is formed of two main structural domains that are independently folded, an N-terminal domain (NTD) and a C-terminal domain (CTD). The two domains are capable of binding to RNA but each uses a different mechanism and the contribution of both domains is required for optimal RNA binding [<xref rid="bib77" ref-type="bibr">77</xref>,<xref rid="bib78" ref-type="bibr">78</xref>]. In the central region there is a third domain, the Ser/Arg (SR rich) linker, which acts as a third RNA binding domain [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>].</p><p id="p0195">Sequencing of N protein of SARS-CoV-2 and comparing it to homologous proteins is a crucial point in understanding structural and mechanistic basis of this virus and identifying the critical residues for RNA binding and virus infectivity. Sequencing and phylogenetic analysis of different studies came as follows; N protein was closest to that of bats according to a study based on the first three genomes of novel SARS-CoV-2. Another study reported N protein of SARS-CoV-2 to share 94% identity with both bat SARS-like CoVs and human SARS-CoV-1 [<xref rid="bib47" ref-type="bibr">47</xref>]. Sequencing of N protein encoding regions along genome datasets revealed high conservation indicating that SARS-CoV-2 shares identical characteristics with other CoVs. Similarity with other N proteins of SARS-CoV-1, MERS-CoV and HCoV-OC43 was found to be 89.74%, 48.59% and, 35.62%, respectively, as observed from Clustal Omega multiple sequence alignment [<xref rid="bib80" ref-type="bibr">80</xref>]. However, crystal structure of the N protein revealed a unique nucleotide binding pocket in NTD which can be a potential drug target. The SARS-CoV-2 N-NTD crystal showed orthorhombic crystal with 4 monomers which was different from SARS-CoV-1 N-NTD [<xref rid="bib80" ref-type="bibr">80</xref>]. Being abundantly expressed and highly immunogenic, N protein of SARS-CoV-2 represents a good target for drug design.</p><p id="p0200">ORF 10: formed of 117 nucleotides and codes for a 38 amino acid short protein [<xref rid="bib46" ref-type="bibr">46</xref>]. It was depicted that this protein has no comparative proteins in the NCBI GenBank Database [<xref rid="bib53" ref-type="bibr">53</xref>]. A study by Tang et al. also reported that ORFs from SARS-CoV-2 were found to be conserved in other related viruses with the exception for ORF8 and ORF 10 [<xref rid="bib68" ref-type="bibr">68</xref>]. It is therefore thought that this protein is opt be used to distinguish SARS-CoV-2 infection more rapidly than PCR based strategies [<xref rid="bib52" ref-type="bibr">52</xref>].</p><p id="p0205">It is worth mentioning that SARS-CoV-2 lacks the gene encoding hemagglutinin-esterase (HE) which is a structural protein characteristically present in a subset of beta coronaviruses and thought to be involved in cell entry mechanisms [<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib47" ref-type="bibr">47</xref>]. As for the 5&#8242;- and 3&#8242;-UTR sequences, they are similar to those of other betacoronaviruses sharing nucleotide identities of more than 83% [<xref rid="bib47" ref-type="bibr">47</xref>].</p></sec></sec><sec id="sec1.2"><label>1.2</label><title>Molecular phylogeny and divergence between SARS-CoV-2 and related coronaviruses</title><p id="p0210">The importance of phylogenetic studies and multiple sequence alignments lies in their ability to identify the mutations which enabled SARS-CoV-2 to acquire its characteristic pathogenic traits and cross species. Scienti&#64257;c literature has examples that show how even single point mutations in virus proteins can alter their pathogenesis and biology significantly [<xref rid="bib61" ref-type="bibr">61</xref>,<xref rid="bib73" ref-type="bibr">73</xref>].</p><sec id="sec1.2.1"><label>1.2.1</label><title>Viral evolution</title><p id="p0215">Several studies showed that the genome of SARS-CoV-2 shares high nucleotide similarity with bat SARS-like CoVs more than with human SARS-CoV-1 [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib81" ref-type="bibr">81</xref>]. All studies point to bats as the natural host of SARS-CoV-1, MERS-CoV and SARS-CoV-2. Two bat coronaviruses (BatCoV RaTG13 and BatCoV RmYN02) were found to share approximately 95% sequence identity with SARS-CoV-2 [<xref rid="bib81" ref-type="bibr">81</xref>,<xref rid="bib82" ref-type="bibr">82</xref>]. However, the intermediate host which caused SARS-CoV-2 to evolve and infect human has not been fully confirmed yet. Pangolins were the first -and so far the most-suggested intermediate hosts. Several studies reported that the critical functional sites of the S protein are almost identical in pangolin CoV and SARS-CoV-2 assuming that in one scenario, pangolins have provided a partial spike gene to the SARS-CoV-2 [<xref rid="bib68" ref-type="bibr">68</xref>,<xref rid="bib83" ref-type="bibr">[83]</xref>, <xref rid="bib84" ref-type="bibr">[84]</xref>, <xref rid="bib85" ref-type="bibr">[85]</xref>]. SARS-CoV-2 E and M proteins were also found to share high structural similarity to their counterparts from bat and pangolin CoVs [<xref rid="bib73" ref-type="bibr">73</xref>]. A second scenario assumed that although the amino acid similarity between the RBD of SARS-CoV-2 and that of pangolin (97.4%) is higher than the similarity with that of bat CoVs (89.2%), SARS-CoV-2 and pangolin CoVs may have originated independently where cross-species transmission from bats took place [<xref rid="bib86" ref-type="bibr">86</xref>]. Another opinion about pangolins role in SARS-CoV-2 is that pangolins are natural hosts for <italic toggle="yes">Betacoronaviruses</italic> but does not support that SARS-CoV-2 emerged directly from pangolin CoV [<xref rid="bib87" ref-type="bibr">87</xref>]. As depicted by some studies, other possible intermediate hosts that may have transmitted SARS-CoV-2 to human include snakes and turtles [<xref rid="bib88" ref-type="bibr">88</xref>]. Yet, a study by Zhang et al. refuted snakes being the intermediate host for SARS-CoV-2 [<xref rid="bib89" ref-type="bibr">89</xref>]. Several molecular phylogeny studies still need to be conducted to understand how SARS-CoV-2 evolved and determine its intermediate host, if any.</p><p id="p0220">Studies comparing SARS-CoV-2 to other human CoVs showed that SARS-CoV-2 genome shared 79&#8211;82% nucleotide identity with human SARS-CoV-1 [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib90" ref-type="bibr">90</xref>] and was found to be less related to and distant from MERS-CoV [<xref rid="bib90" ref-type="bibr">90</xref>]. Although at the whole genome level SARS-CoV-2 was closer to bat CoVs, the receptor binding domain of SARS-CoV-2 was reported to be closer to that of SARS-CoV-1 [<xref rid="bib90" ref-type="bibr">90</xref>]. Studies of the amino acid substitutions in the proteins of SARS-CoV-2 are thus important to explain how these proteins differ structurally and functionally from those of SARS-CoV-1. The major distinction between SARS-CoV-2 and SARS-CoV-1 was found to be in orf 3, Spike and orf8 as mentioned earlier [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib68" ref-type="bibr">68</xref>]. Specifically, the S1 subunit of the spike protein of SARS-CoV-2 displayed a higher binding affinity to human angiotensin converting enzyme II (ACE-2) than that of SARS-CoV-1. This was attributed to difference in 5 amino acid residues in the RBD of S1 which affected the 3D structure of the spike protein [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib52" ref-type="bibr">52</xref>].</p></sec><sec id="sec1.2.2"><label>1.2.2</label><title>Mutations in SARS-CoV-2 genome</title><p id="p0225">Phylogenetic analysis of SARS-CoV-2 genome has been paralleled by studying mutations in its genome to determine the different variants and most common mutation sites. This should provide better understanding for the continuous viral evolution which might affect its spread and pathogenicity. In addition to this, it helps in accurate design for primers and probes. A study by Koyama et al. identified 5775 genome variants among 10,022 studied genomes, 1905 of which were found in ORF1ab. Mutations in the RdRp (nsp12) were detected as well as deletion in the 3&#8242;-5'exonuclease [<xref rid="bib53" ref-type="bibr">53</xref>]. In another study, a number of 116 mutations were found in 95 analysed genomes, the most common were found in ORF1ab, ORF8 and the N gene [<xref rid="bib52" ref-type="bibr">52</xref>]. A study by Tang et al. identified 149 mutation sites across 103 sequences and categorized SARS-CoV-2 viruses into two major lineages, L and S lineages with L being the major lineage (~70%). This was based on the observation mentioned in the study where 101 of 103 studied SARS-CoV-2 sequences displayed complete linkage with one of two SNPs (single nucleotide polymorphism); L lineage where T28,144 is in the codon of Leucine and S lineage where C28,144 is in the codon of Serine [<xref rid="bib68" ref-type="bibr">68</xref>]. Homology analysis also reported that although sequence variation among SARS&#8208;CoV&#8208;2 genomes was low, mutation hotspots in ORFs 1a, S, 8, and N were detected and suggests this might sometimes be the reason behind the false negative RT-PCR result which is not uncommon in SARS-CoV-2 diagnosis [<xref rid="bib46" ref-type="bibr">46</xref>]. A genotyping analysis also showed that the genes encoding RNA polymerase, RNA primase, S and N proteins undergo frequent mutations [<xref rid="bib91" ref-type="bibr">91</xref>]. It is therefore clear that studying mutations in SARS-CoV-2 is critical for understanding viral pathogenesis and vaccine development.</p></sec><sec id="sec1.2.3"><label>1.2.3</label><title>Virus life cycle</title><p id="p0230">The inhaled SARS-CoV-2 enters the human cell through three main steps which include receptor binding, proteolysis, and activation of membrane fusion within endosomes [<xref rid="bib92" ref-type="bibr">92</xref>]. The Receptor binding of S glycoprotein with ACE2 receptor involves conformational changes of both moieties. Proteolysis occurs by different proteases for example furin, trypsin, cathepsins, transmembrane protease serine protease-2 (TMPRSS-2), TMPRSS-4, or human airway trypsin-like protease (HAT) [<xref rid="bib93" ref-type="bibr">93</xref>]. In case of SARS-CoV-2, TMPRSS2 and lysosomes proteases hydrolyze S protein into two parts: S1 and S2. This process is highly facilitated by the presence of multibasic amino acids at the cleavage point [<xref rid="bib94" ref-type="bibr">94</xref>,<xref rid="bib95" ref-type="bibr">95</xref>] The S1 part contains the receptor binding domain (RBD) which attaches to the cell receptors and S2 part is responsible for fusion with cell membrane [<xref rid="bib96" ref-type="bibr">96</xref>]. At the boundary between S1/S2, a proprotein convertase motif was found which is known to be the hallmark of pathogenicity of avian influenza. However, Wall et al. (2020) found that this motif did not improve the entry of SARS-CoV-2 inside the cells. One interesting finding was reported by Ou et al. who speculated SARS-CoV-2 S protein can react with the receptor by protease-independent entry which may explain the rapid progress of this disease. After attachment is completed, the virus transmembrane undergoes fusion through an endocytic pathway where viral RNA is freed into the cytoplasm [<xref rid="bib97" ref-type="bibr">97</xref>]. The endosomal pathway guarantees the integrity of plasma membrane during passage of any extracellular substance. The interior of the endosomes is characterized by acidic pH due to the presence of a proton pump inside it [<xref rid="bib98" ref-type="bibr">98</xref>]. Moreover, cysteine proteases, likely cathepsin B or L, enabled the pH-dependent release of the virus from the cytoplasm [<xref rid="bib95" ref-type="bibr">95</xref>].</p><p id="p0235">The ACE2 receptor is a zinc binding carboxypeptidase found in different body cells like type II pneumocytes, myocardial cells, cholangiocytes, enterocytes, and oral mucosal epithelium [<xref rid="bib99" ref-type="bibr">99</xref>]. The interacting region in this receptor composes of fifteen residues ordered into a beta-sheet conformation surrounded by two capping loops. This region is highly conserved between SARS-CoV-1 and SARS-CoV-2 and share 76% similarity [<xref rid="bib100" ref-type="bibr">100</xref>]. However, some modification in the amino acid residues L455, F486, Q493, and N501 improved the interaction in SARS-CoV2. Ortega et al. reported the presence of two loops around the RBD of S protein which strengthen the receptor binding due to involvement of more molecules in the binding [<xref rid="bib101" ref-type="bibr">101</xref>]. Moreover, phenylalanine in the loop (F486) can bind to hydrophobic pocket of ACE2 and helps in receptor recognition [<xref rid="bib102" ref-type="bibr">102</xref>]. Many studies concluded that ACE2 receptor mutation does not affect its binding to S protein or promotion of S protein syncytia formation [<xref rid="bib103" ref-type="bibr">103</xref>,<xref rid="bib104" ref-type="bibr">104</xref>].</p><p id="p0240">The binding between the S protein and ACE2 receptor itself was puzzling and affected the infectivity of SARS-CoV2. The RBD has two positions, standing up and lying down to enable receptor binding and immune evasion, respectively. It was found that SARS-CoV-1 RBD is always in the standing position while SARS-CoV-2 is in the lying down state. Thus, SARS-CoV-2 has higher binding to ACE2 receptor and less accessibility to the immune system. This hidden RBD also contributed to the difficulty of treatment and vaccination.</p><p id="p0245">The activation of ACE2 receptors lead to alteration in the renin-angiotensin-aldosterone system (RAAS) which is the reason behind the inflammatory lung disease accompanied with SARS-CoV-2 infection. Moreover, the proinflammatory mediators such as interleukin-8/cytokine-induced neutrophil chemoattractant-3 and interleukin-6 expression lead to vasoconstriction and pulmonary edema [<xref rid="bib105" ref-type="bibr">105</xref>].</p><p id="p0250">After the virus entry inside the cell, synthesis of RNA starts using two different processes: genome replication and transcription of subgenomic RNA [<xref rid="bib106" ref-type="bibr">106</xref>]. The replication is initiated by the translation of gene 1, which encodes the replicase enzyme. This enzyme is processed by two viral proteases, a papain-like protease (PLpro) and a 3C-like protease (Mpro) into 16 non-structural proteins [<xref rid="bib107" ref-type="bibr">107</xref>]. The cleavage of N-terminus of the replicase poly-protein is carried out by PLpro into nsp1, nsp2 and nsp3. Moreover, PLpro is believed to antagonize the host's innate immunity by interfering with type I interferon signaling pathway [<xref rid="bib108" ref-type="bibr">108</xref>]. Mpro, on the other hand, is important in maturation of non-structural proteins. These nsps combine into the replicase&#8211;transcriptase complex (RTC) for RNA replication and transcription of the sub-genomic RNAs. Afterwards, the RNA-dependent RNA polymerase (RdRp), which is encoded by the RNA virus begins the continuous process of RNA synthesis from the RNA templates. The replication involves the formation of negative strand RNA to serve as a template for genomic RNA. It is worth mentioning that RdRp sequence is homologues in both of SARS-CoV-1 and SARS-CoV-2 [<xref rid="bib109" ref-type="bibr">109</xref>].</p><p id="p0255">Subgenomic RNAs acts as mRNAs for the structural and accessory genes which are downstream of the replicase polyproteins. The transcription process to synthesize subgenomic RNA is highly complicated among positive strand RNA viruses. It requires initiation and premature termination. Moreover, the subgenomic RNA contains at 5&#8217; end, a leader sequence which is unique in coronaviruses. This 5&#8242; leader sequence may protect SARS-CoV-1 mRNAs from nsp1-induced endonucleolytic cleavage of capped mRNAs, which explains the effective buildup of viral mRNAs and proteins during the infection [<xref rid="bib106" ref-type="bibr">106</xref>]. The transcription process is regulated by transcription-regulating sequences (TRSs) located at the 3&#8242; end of the leader sequence (TRS-L) and preceding each viral gene (TRS-B). The transcription process is discontinuous because RdRp ceases the transcription at each TRS sequence. Finally, the subgenomic RNA is translated into structural (N, M, E and S), non-structural and accessory proteins (AP), assembling new virions.</p><p id="p0260">After replication, transcription, and translation, the assembly of virion particles takes place by cooperation between endoplasmic reticulum and Golgi apparatus [<xref rid="bib99" ref-type="bibr">99</xref>]. Meanwhile, the assembly of SARS-CoV-2 virus is not yet studied. Therefore, information in the following paragraphs is based on the study of SARS-CoV-1 in general. The release of the virions from coronavirus-infected cells consists of two processes, assembly of the helical nucleocapsids and of the viral envelopes.</p><p id="p0265">First, the assembly of helical nucleocapsids occurs in the cytoplasm [<xref rid="bib110" ref-type="bibr">110</xref>]. The nucleocapsid composes of N protein and RNA. Sometimes the M protein could also be found [<xref rid="bib111" ref-type="bibr">111</xref>]. N protein is a multifunctional protein. It binds to leader RNA to maintain the RNA conformation suitable for replication and transcription. It binds to viral RNA genome and packs it into a helical nucleocapsid structure referred to as ribonucleoprotein (RNP) complex [<xref rid="bib79" ref-type="bibr">79</xref>]. The packaging of RNA into virus like particles (VLP) was found to be nucleocapsid dependant [<xref rid="bib112" ref-type="bibr">112</xref>]. It is also involved in host pathogen interactions and viral pathogenicity; it blocks the S phase in mammalian cells [<xref rid="bib113" ref-type="bibr">113</xref>], in addition to being highly immunogenic as its CTD acts as an interferon antagonist [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>]. As depicted from studies on N protein of related coronaviruses, NTD binds to the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplex complex, CTD is responsible for oligomerization which is crucial for viral ribonucleoprotein packaging and SR rich linker is responsible for primary phosphorylation [<xref rid="bib80" ref-type="bibr">80</xref>]. N protein also binds to nsp3 and M proteins. These interactions are key for the formation of replicase-transcriptase complex (RTC) and packaging of the genome into VLP [<xref rid="bib78" ref-type="bibr">78</xref>,<xref rid="bib112" ref-type="bibr">112</xref>].</p><p id="p0270">Second the viral envelope assembly occurs in the intracellular membranes. Normally, enveloped viruses obtain their membranes through budding of the viral nucleocapsid through cellular membranes. SARS-CoVs assemble at the intracellular membranes in the Endoplasmic reticulum-Golgi intermediate compartment (or ERGIC) after infection. From there, they bud within the lumen and are consequently carried outside the cell through &#8216;exocytosis&#8217; within the cargo vesicles [<xref rid="bib49" ref-type="bibr">49</xref>]. The viral membrane proteins play a clear role in formation of the viral envelope. As studied in SARS-CoV-1, M and E proteins are required for virion assembly and release but E protein is found in trace amounts. Thus, the assembly depends mainly on interactions among M proteins [<xref rid="bib110" ref-type="bibr">110</xref>]. In addition, M protein provides the matrix for nucleocapsid attachment and thus budding takes place. The other proteins such as S and E, are integrated into the lattice through interactions with M, whereas N and viral RNA interact with M C-terminal domain, which is exposed to the cytosol [<xref rid="bib114" ref-type="bibr">114</xref>]. Other studies showed that protein E is very important in pathogenesis of SARS-CoV-1 and proved that the absence of E protein lead to virus attenuation [<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib115" ref-type="bibr">115</xref>].</p></sec></sec></sec><sec id="sec2"><label>2</label><title>Treatment and drug discovery</title><sec id="sec2.1"><label>2.1</label><title><italic toggle="yes">In silico</italic> and <italic toggle="yes">in vitro</italic> drug targeting for COVID-19</title><p id="p0275">Finding a treatment for COVID-19 has become the focal point of research in the past few months. Several previously known drugs have been tested for their activity against SARS-CoV-2. In this review, we will try to summarize the potential drug candidates for SARS-CoV-2 treatment that were deduced from <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic> studies.</p><p id="p0280">There are three main strategies for developing an anti-SARS-CoV-2 drug, the first is to test already existing antivirals and repurposing of therapeutic drugs that were reported to have antiviral activity, the second depends on using <italic toggle="yes">in silico</italic> molecular docking to screen molecular databases for compounds with a therapeutic effect on SARS-CoV-2. The third strategy depends on using the genomic information of the virus to develop novel targeted drugs from scratch which might take very long time.</p><p id="p0285">Based on the first strategy, different antiviral drugs were tested. According to some studies, it was found that the common antiviral drug Ribavirin showed no effect against SARS-CoV-2 while the new antiviral drug Remdesivir effectively inhibited viral replication [<xref rid="bib116" ref-type="bibr">116</xref>]. It is worth mentioning that an <italic toggle="yes">in silico</italic> docking study to analyse the binding sites of potential protease (PLpro) inhibitors showed multiple active site residues in the protease structure for Remdesivir while for the other tested ligands (nelfinavir, ritonavir, lopinavir and aketoamide), there was only one active site residue [<xref rid="bib117" ref-type="bibr">117</xref>]. Testing different combinations of drugs (Lopinavir, Oseltamivir and Ritonavir) using molecular docking and dynamics were also investigated [<xref rid="bib118" ref-type="bibr">118</xref>]. Another <italic toggle="yes">in silico</italic> study explored the molecular mechanism of binding between Mpro and its suggested inhibitors. The study referred to particular regions of the Mpro pocket as the &#8220;anchor&#8221; site and reported a newly discovered mechanism in which the binding of the ligand improved when part of it occupied this anchor site inside Mpro pocket. The study also suggested nelfinavir as a potent drug against SARS-CoV-2 [<xref rid="bib119" ref-type="bibr">119</xref>].</p><p id="p0290">As an application to drug repurposing strategy, chloroquine and Hydroxychloroquine were tested as they were previously reported to effectively inhibit SARS-CoV-1 viral replication <italic toggle="yes">in vitro</italic>, Hydroxychloroquine being more effective [<xref rid="bib120" ref-type="bibr">120</xref>]. Combining hydroxychloroquine and azithromycin showed synergistic effect on SARS-CoV-2 <italic toggle="yes">in vitro</italic> [<xref rid="bib121" ref-type="bibr">121</xref>]. Determining the therapeutic efficiency and cardiovascular side effects of hydroxychloroquine has been a focal point in clinical studies recently [<xref rid="bib122" ref-type="bibr">122</xref>].</p><p id="p0295">According to the second strategy, molecular databases were screened for compounds with a therapeutic effect on SARS-CoV-2. Homology modelling was used to build all possible SARS-CoV-2 protein structures for screening of potential inhibitor molecules from marketed drugs. Important protein targets in SARS-CoV-2 include PLpro, Mpro, RdRp, helicase in addition to structural proteins. A series of antivirus drugs, antibacterials, muscle relaxants, anti-tussive drugs and a spectrum of natural products were reported to bind with high affinity to PLpro, the papain-like protease of SARS-CoV-2. The well-fitting of the anti-asthmatic montelukast drug into the active pocket of Mpro, the chymotrypsin-like protease of SARS-CoV-2, was also reported. Potential inhibitors of RNA-dependant RNA polymerase (RdRp), helicase and structural proteins like S protein were also depicted in this study [<xref rid="bib108" ref-type="bibr">108</xref>].</p><p id="p0300">Zhou et al. used network proximity analyses of different drug targets and SARS&#8211;host interactions in the human interactome where they reported three possible combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) to be efficient against SARS-CoV-2 [<xref rid="bib123" ref-type="bibr">123</xref>].</p><p id="p0305"><italic toggle="yes">In silico</italic> docking studies using medicinal plant libraries have also been conducted for the identification of potential anti-viral phytochemicals. One study screened 32,297 compounds and suggested anti-SARS-CoV-2 molecules that need further investigations [<xref rid="bib124" ref-type="bibr">124</xref>]. Three phytochemicals were also found to reduce the random movement of SARS-CoV-2 E protein thus inhibiting its function [<xref rid="bib49" ref-type="bibr">49</xref>]. Another study showed that luteolin, the main flavonoid in a traditional Chinese medicinal formula, binds strongly to the active sites of the main protease (PLpro) of SARS-CoV-2 indicating a possible antiviral activity [<xref rid="bib116" ref-type="bibr">116</xref>]. A study carried out by Abdelli et al. tested the binding affinity for ACE2 receptor by several natural products. This study showed that Isothymol showed the highest binding score and the most stable interaction with ACE2 receptor [<xref rid="bib125" ref-type="bibr">125</xref>]. Joshi et al. studied about 318 phytochemicals from 11 plants and then screened their activity against main protease (Mpro) and ACE2 [<xref rid="bib126" ref-type="bibr">126</xref>]. Moreover, they reported that the typical pharmacophore consists of hydrophobic, aromatic, negative, and positive functional groups in addition to hydrogen bond acceptor and hydrogen bond donor groups.</p><p id="p0310">The third strategy depends on using homology modelling of viral proteins to discover possible ligand binding sites and predict binding mechanisms. This is crucial for designing new drugs. An example to this is the study by Shankar et al. which suggested two ligands that can possibly be developed into antivirals against SARS-CoV-2, the first (an aza-peptide epoxide) can be used to irreversibly inhibit viral protease and the second as a viral replication inhibitor [<xref rid="bib60" ref-type="bibr">60</xref>]. Another study used computer-aided drug design to identify a mechanism-based inhibitor of SARS-CoV-2 Mpro and screened more than 10,000 compounds for their ability to inhibit this protease [<xref rid="bib63" ref-type="bibr">63</xref>]. A study on the crystal structure of nucleocapsid protein of SARS-CoV-2 also revealed unique drug targeting sites that can be used to design new antiviral agents [<xref rid="bib80" ref-type="bibr">80</xref>]. An <italic toggle="yes">in silico</italic> study by Liu et al. also identified potential compounds possibly targeting Mpro, the main protease of SARS-CoV-2 [<xref rid="bib127" ref-type="bibr">127</xref>]. In their study, Han and Kral designed inhibitors from the protease domain (PD) of ACE2 and by using the Molecular dynamics simulations, the &#945;-helical peptides were the most stable and highly specific to SARS-CoV-2 [<xref rid="bib128" ref-type="bibr">128</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>On-going clinical trials</title><p id="p0315">A lot of clinical trials have proliferated since the beginning of COVID-19 pandemic to slow its spread. All the on-going clinical trials are registered either in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link> or the International Clinical Trials Registry Platform (ICTRP) of the WHO. Most of registered clinical trials are grouped either for treatment or prevention of COVID-19. A lot of antivirals drugs previously used for Influenza, Ebola, HIV or Malaria were repurposed for COVID-19 disease. For example, the combination of Lopinavir and Ritonavir was tested in 34 investigational clinical trials. They are both protease inhibitor used originally in treatment of HIV infection [<xref rid="bib129" ref-type="bibr">129</xref>]. However, Cao et al. mentioned that this combination showed no benefit beyond the standard care. The standard care includes providing supplemental oxygen, antibiotic agents, noninvasive and invasive ventilation, vasopressor support, and extracorporeal membrane oxygenation (ECMO) [<xref rid="bib130" ref-type="bibr">130</xref>]. Moreover, some drugs were directed against the ACE2 receptor such as Losartan, an angiotensin receptor antagonist [<xref rid="bib131" ref-type="bibr">131</xref>]. Randomized double-blinded placebo-controlled phase I clinical trials are testing safety of Losartan especially in COVID-19 respiratory failure patients [<xref rid="bib132" ref-type="bibr">132</xref>]. Other clinical trials targeted the entry of SARS-CoV-2 like phase 2 clinical trial on Camostat mesilate (CM), an inhibitor of TMPRSS2 [<xref rid="bib133" ref-type="bibr">133</xref>]. In addition, amiodarone, calcium channel blocker, was used against Ebola virus to block its entry by blocking the ion channels [<xref rid="bib134" ref-type="bibr">134</xref>]. A phase 3 clinical trial now is directed towards using Verapamil and Amiodarone against COVID-19 [<xref rid="bib135" ref-type="bibr">135</xref>]. Furthermore, the use of monoclonal antibodies against COVID-19 was investigated in different studies. The most important study was on using Tocilizumab, an anti-IL6 drug which reached Phase 3 [<xref rid="bib129" ref-type="bibr">129</xref>]. Moreover, some monoclonal antibodies were developed against the S protein as a part of the ACTIV-3 master protocol sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) [<xref rid="bib136" ref-type="bibr">136</xref>]. These antibodies, VIR-7831 [<xref rid="bib137" ref-type="bibr">137</xref>], BRII-196 and BRII-198 [<xref rid="bib138" ref-type="bibr">138</xref>] are used for hospitalized patients and reached Phase 3 clinical trials.</p><p id="p0320">As of June 25, the RECOVERY trial (Randomized Evaluation of COVID-19 Therapy) which is a multicenter, open-label trial sponsored by the National Health Service in the United Kingdom announced that dexamethasone with standard of care therapy decreased the mortality rate in confirmed COVID-19 cases by one third. Results of this clinical trial are still not published in a peer review journal but its results were announced in Nature news and NIH site (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19" id="intref0015">https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/dexamethasone/" id="intref0020">https://www.covid19treatmentguidelines.nih.gov/dexamethasone/</ext-link>).</p><p id="p0325">Some clinical trials depended on previous computational testing of drugs. For example, Famotidine effectiveness was predicted from <italic toggle="yes">in silico</italic> screening of several FDA licensed compound against the SARS-CoV 2 protease Plpro catalytic site and it showed a high computationally score and favorable pharmacokinetic and safety profile. Now, Famotidine is tested in a multisite adaptive trial phase 3 for COVID-19 in hospitals [<xref rid="bib139" ref-type="bibr">139</xref>]. Moreover, Umifenovir is a Russian antiviral drug whose activity was investigated <italic toggle="yes">in Silico</italic> by Huynh et al. [<xref rid="bib119" ref-type="bibr">119</xref>] against Mpro and it is in now in phase 4 clinical trial [<xref rid="bib140" ref-type="bibr">140</xref>]. Being highly effective against SARS-CoV-2 protease Mpro [<xref rid="bib141" ref-type="bibr">141</xref>], Remedesivir was used in a randomized, double-blinded, placebo-controlled trial in China for COVID-19. Interestingly, it was reported that Remdesivir helped the patients to have a clinical improvement in shorter time than those receiving placebo [<xref rid="bib142" ref-type="bibr">142</xref>]. However, in November 2020, WHO conditionally recommended against the use of Remedesivir in hospitalized patients due to lack of evidence on better outcomes for its usage in comparison to placebo [<xref rid="bib143" ref-type="bibr">143</xref>]. Other drugs that are being clinically used include Chloroquine and hydroxychloroquine which are believed to impair virus replication at early stages as well as interference with post-translational modifications of the viral proteins. Several clinical studies have so far been conducted to determine the therapeutic and prophylactic activity as well as the safety of hydroxychloroquine [<xref rid="bib122" ref-type="bibr">122</xref>,<xref rid="bib144" ref-type="bibr">144</xref>]. A study that used molecular modelling suggested that chloroquine binds with high affinity to sialic acid and gangliosides inhibiting the binding of N-terminal domain of the S protein of SARS-CoV-2 to gangliosides [<xref rid="bib116" ref-type="bibr">116</xref>].</p></sec></sec><sec id="sec3"><label>3</label><title>Prevention: COVID-19 vaccine development</title><p id="p0330">The immediate production of a potent vaccine is obviously mandatory to reduce not only the tragic numbers of infections and fatalities caused by the COVID-19 pandemic, but also its disastrous impact on world economies. Even though vaccine development is lagging behind the pandemic spread, it is still essential and critical, since the infection is still growing all over the world. Moreover, COVID-19 infection might be staying for a long time, and become a seasonal disease, just like influenza [<xref rid="bib145" ref-type="bibr">145</xref>]. Pharmaceutical companies and academic institutions all around the world are working on evolving a SARS-CoV-2 vaccine [<xref rid="bib146" ref-type="bibr">146</xref>]. It is well believed now that our world will not come back to normal up until successful vaccines become accessible and a global vaccination program is efficaciously applied.</p><sec id="sec3.1"><label>3.1</label><title>Why is it taking so long?</title><p id="p0335">It usually takes years to develop vaccines for human use, particularly if new technologies, untested for safety or not produced on a large scale, are used. Typically, the development of new vaccines takes around 10&#8211;20 years, with a success of lower than 10%, even for a vaccine that reaches clinical evaluation [<xref rid="bib146" ref-type="bibr">146</xref>].</p><p id="p0340">Chinese researchers swiftly identified SARS-CoV-2 and quickly revealed its genomic sequence [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib147" ref-type="bibr">147</xref>]. The virus was isolated from naso and oropharyngeal swabs, and its sequence, replication properties, and cell culture tropism was determined. SARS-CoV-2 grew in 2 Vero cell types: VeroE6 and Vero CCL81, the viral titers being a little higher in the former type [<xref rid="bib148" ref-type="bibr">148</xref>]. The MERS-CoV and SARS-CoV-1 vaccines developed during the past years provided scientists with crucial knowledge to help develop SARS-CoV-2 vaccines, owing to their genetic resemblance with SARS-CoV- 2. The challenge is still great though, since all CoV vaccine candidates proved unsuccessful in primary clinical evaluation, with none being forwarded to licensing [<xref rid="bib149" ref-type="bibr">149</xref>].</p><p id="p0345">We know from these previous studies that the S protein, which binds with the ACE2 host receptor, is an excellent target for a vaccine. Antibodies can neutralize the virus by targeting the spike and interfering with this binding. Scientists determined SARS-CoV-2 S protein structure by cryo&#8211;electron microscopy in record time [<xref rid="bib40" ref-type="bibr">40</xref>]. Hence, we already have a perfect antigen to be used for advanced vaccine platforms. Basically, two essential steps are required before putting a vaccine into clinical trials.</p><p id="p0350">To begin with, to confirm that a vaccine is protective, it should undergo preclinical evaluation using suitable animal models. Only a few animal models are presently available for the novel SARS-CoV &#8722;2 [<xref rid="bib146" ref-type="bibr">146</xref>]. Since wild-type mice do not support the growth of the virus, studies using the human angiotensin-converting enzyme 2 (hACE2) transgenic mice infected with SARS-CoV-2 have been carried out to study its pathogenicity. However, the virus only brought about moderate disease in these transgenic mice [<xref rid="bib150" ref-type="bibr">150</xref>]. In addition, of the non-human primates, rhesus macaques were reported to be more susceptible to SARS-CoV-2 than cynomolgus macaques and marmosets. Recent studies also reported that SARS-CoV-2 may cause moderate to serious pulmonary infections in ferrets and hamsters [<xref rid="bib151" ref-type="bibr">151</xref>].</p><p id="p0355">Next, we need to confirm the safety of these developed SARS-CoV-2 vaccines. Safety is the most critical aspect to consider during vaccine development, and it is important that we ought not to fast track COVID-19 vaccines without satisfactory secure guarantees. Some SARS-CoV-1 vaccines that were previously evaluated in animal models resulted in complications. For example, earlier reports have implicated that full-length S protein can induce serious liver damage and enhanced infection, known as antibody-dependent enhancement (ADE), due to S protein specific antibodies [<xref rid="bib152" ref-type="bibr">152</xref>]. ADE results when non-neutralizing antibodies against virus proteins enhance virus infectivity through augmenting viral entry into host cells [<xref rid="bib153" ref-type="bibr">153</xref>]. ADE has been reported for different coronaviruses. This phenomenon occurs due to a reduction in the binding strength of neutralizing antibodies to the virus, which switches these antibodies into suboptimal&#8212;non neutralizing ones. This decrease in affinity may be mainly due to a change in the conformation of the viral S-protein. Nevertheless, other factors contributing to antigen drift and antigenic determinant changes may also have a role [<xref rid="bib154" ref-type="bibr">154</xref>]. In addition, an inactivated whole virus vaccine in non-human primates and a VLP vaccine in mice were found to protect from infection but showed an immunopathologic-type lung disease in challenged animals [<xref rid="bib155" ref-type="bibr">155</xref>]. Immunization with vaccines expressing SARS-CoV-1 S protein was reported to cause enhanced hepatitis in ferrets as well [<xref rid="bib156" ref-type="bibr">156</xref>].</p><p id="p0360">After that, to ensure constant quality, human vaccines should be manufactured using procedures that adhere to current Good Manufacturing Practice (cGMP), which demands committed facilities and qualified personnel. Such processes are not available yet for most vaccine candidates and hence need to be generated from scratch.</p><p id="p0365">As soon as reliable preclinical data and preliminary cGMP quality vaccine batches are available, clinical trials may start. These begin with phase I trials to assess the vaccine safety in a small number of individuals. Phase 2 trials are next, where preparation and doses are determined to verify vaccine effectiveness, and lastly phase 3 trials, where vaccine effectiveness and safety are required to be validated in a larger group of people. However, in emergencies like this pandemic, this pathway may be pressed, and a quick plan might be developed to gain a license by regulatory agencies [<xref rid="bib157" ref-type="bibr">157</xref>]. However, this should be carried out carefully to avoid catastrophic outcomes.</p><p id="p0370">Another important aspect is that we will need to build large scale production capacities to manufacture satisfactory quantities of cGMP-quality vaccines. Current infrastructure may be utilized for conventional vaccines, however, for vaccines using new technologies, e.g., mRNA, it will be challenging and will obviously take some time [<xref rid="bib157" ref-type="bibr">157</xref>].</p></sec><sec id="sec3.2"><label>3.2</label><title>Categories of SARS-CoV-2 Vaccines under development</title><p id="p0375">So far, 10 separate technology platforms are being researched to generate a successful SARS-CoV-2 vaccine, however, 4 main types are currently in Phase 3 clinical evaluation (<xref rid="tbl2" ref-type="table">Table 2</xref>
). These technologies are implementing novel approaches for concentrating on the COVID-19 infection mechanisms, accelerating development and addressing COVID-19 mechanisms that target precise population categories, like the old-aged, expecting women, and immunocompromised individuals [<xref rid="bib158" ref-type="bibr">158</xref>,<xref rid="bib159" ref-type="bibr">159</xref>].<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Candidate COVID-19 Vaccines in Phase 3 clinical evaluation according to the WHO as of January 3, 2021 [<xref rid="bib159" ref-type="bibr">159</xref>].</p></caption><alt-text id="alttext0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">ID</th><th colspan="1" rowspan="1">Vaccine platform acronymn</th><th colspan="1" rowspan="1">Vaccine platform description</th><th colspan="1" rowspan="1">Type of candidate vaccine</th><th colspan="1" rowspan="1">Route of administration</th><th colspan="1" rowspan="1">Developers</th><th colspan="1" rowspan="1">Phase</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 vaccine (inactivated)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Sinovac Research and Development Co., Ltd</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine (Vero cell)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Sinopharm&#160;+&#160;Wuhan Institute of Biological Products</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine (Vero cell)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Sinopharm&#160;+&#160;Beijing Institute of Biological Products</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">VVnr</td><td align="left" colspan="1" rowspan="1">Viral vector (Non-replicating)</td><td align="left" colspan="1" rowspan="1">ChAdOx1-S - (AZD1222) (Covishield)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">AstraZeneca&#160;+&#160;University of Oxford</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">VVnr</td><td align="left" colspan="1" rowspan="1">Viral vector (Non-replicating)</td><td align="left" colspan="1" rowspan="1">Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">VVnr</td><td align="left" colspan="1" rowspan="1">Viral vector (Non-replicating)</td><td align="left" colspan="1" rowspan="1">Gam-COVID-Vac Adeno-based (rAd26-S&#160;+&#160;rAd5-S)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute; Health Ministry of the Russian Federation</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">VVnr</td><td align="left" colspan="1" rowspan="1">Viral vector (Non-replicating)</td><td align="left" colspan="1" rowspan="1">Ad26.COV2&#183;S</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Janssen Pharmaceutical</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">PS</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Novavax</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">RNA based vaccine</td><td align="left" colspan="1" rowspan="1">mRNA -1273</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Moderna&#160;+&#160;National Institute of Allergy and Infectious Diseases (NIAID)</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">RNA based vaccine</td><td align="left" colspan="1" rowspan="1">BNT162 (3 LNP-mRNAs)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">BioNTech&#160;+&#160;Fosun Pharma; Jiangsu Provincial Center for Disease Prevention and Control&#160;+&#160;Pfizer</td><td align="left" colspan="1" rowspan="1">Phase 2/3</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">PS</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Recombinant SARS-CoV-2 vaccine (CHO Cell)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Anhui Zhifei Longcom Biopharmaceutical&#160;+&#160;Institute of Microbiology, Chinese Academy of Sciences</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">RNA based vaccine</td><td align="left" colspan="1" rowspan="1">CVnCoV Vaccine</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">CureVac AG</td><td align="left" colspan="1" rowspan="1">Phase 2/3</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">DNA based vaccine</td><td align="left" colspan="1" rowspan="1">INO-4800+electroporation</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Inovio Pharmaceuticals&#160;+&#160;International Vaccine Institute</td><td align="left" colspan="1" rowspan="1">Phase 2/3</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Bharat Biotech International Limited</td><td align="left" colspan="1" rowspan="1">Phase 3</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">VLP</td><td align="left" colspan="1" rowspan="1">Virus like particle</td><td align="left" colspan="1" rowspan="1">Coronavirus-Like Particle COVID-19 (CoVLP)</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Medicago Inc.</td><td align="left" colspan="1" rowspan="1">Phase 2/3</td></tr></tbody></table></table-wrap></p><p id="p0380">According to the WHO, as of January 3, 2021, 172 SARS-CoV-2 vaccine candidates are in pre-clinical development while 60 candidates are in clinical evaluation: 11 in Phase 3, 4 in Phase 2/3, 3 in Phase 2, 22 in Phase 1/2, and 20 in Phase 1 trials [<xref rid="bib159" ref-type="bibr">159</xref>].</p><p id="p0385">The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine on 11 and December 18, 2020, respectively [<xref rid="bib160" ref-type="bibr">160</xref>].</p><p id="p0390">On the other hand, in July 2020, China hurled an emergency use program for essential workers and high risk individuals and has administered more than 4.5 million doses of Sinopharm's two vaccines and Sinovac's CoronaVac. Later, on December 31, 2020, chinese authorities conditionally approved the general public use of Sinopharm vaccine, right after the firm announced its leading vaccine had a 79% efficacy rate in phase 3 trials. Brazil, Indonesia, Turkey, Chile and Singapore signed up for Sinovac's CoronaVac. The United Arab Emirates announced that the Sinopharm vaccine was 86% effective in a phase 3 trials, and was the first other country to approve it to the public, followed by other countries like Pakistan and Egypt. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bbc.com/news/world-asia-china-55498197" id="intref0025">https://www.bbc.com/news/world-asia-china-55498197</ext-link>
<underline>.</underline>
</p><p id="p0395">One of Sinopharm and Sinovac's key advantages is that it can be kept in a standard refrigerator at 2&#8211;8&#160;&#176;C, whereas Moderna's vaccine needs to be stored at &#8722;20&#160;&#176;C and Pfizer's vaccine at &#8722;70&#160;&#176;C. Hence, both Sinovac and Sinopharm vaccines are far more suitable for developing countries which can not store huge vaccine amounts at these low temperatures. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bbc.com/news/world-asia-china-55212787" id="intref0030">https://www.bbc.com/news/world-asia-china-55212787</ext-link>.</p><p id="p0400">Herein, we will summarize recent development efforts, mainly focusing on those that reached Phase 3 clinical evaluation (<xref rid="tbl2" ref-type="table">Table 2</xref>). All of the COVID-19 vaccines that are presently in Phase 3 trials require 2 doses, except one candidate, Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) produced by CanSino Biological Inc./Beijing Institute of Biotechnology, which requires only one dose [<xref rid="bib159" ref-type="bibr">159</xref>].</p><sec id="sec3.2.1"><label>3.2.1</label><title>Inactivated and live attenuated vaccines</title><p id="p0405">Killed vaccines are conventional vaccines with established preparatory technology, which explains why many of the vaccine candidates that already entered clinical evaluation are from this group. These vaccines use cultured SARS-CoV-2 inactivated by physical methods (eg. UV light) or chemical methods (eg. formaldehyde) [<xref rid="bib161" ref-type="bibr">161</xref>]. However, to be effective, these vaccines usually necessitate the presence of an adjuvant and repeated administration. In addition, using the adjuvant alum renders them inappropriate for mucosal delivery and they are poor inducers of cytotoxic CD8<sup>+</sup> T cells, which are probably needed for an effective COVID-19 vaccine [<xref rid="bib162" ref-type="bibr">162</xref>].</p><p id="p0410">CoronaVac is an alum-adjuvant candidate vaccine inactivated using formalin and produced by the Chinese firm Sinovac Biotech. Preclinical studies show incomplete or full protection in macaques exposed to SARS-CoV-2 challenge without detectable ADE [<xref rid="bib163" ref-type="bibr">163</xref>]. Sinovac's phase 2 trials also showed that the vaccine formed neutralizing antibodies without severe adverse reactions [<xref rid="bib164" ref-type="bibr">164</xref>]. In July 2020, phase 3 clinical trials were started to measure the efficacy and safety of Sinovac's vaccine in Brazil, Indonesia and Turkey [<xref rid="bib159" ref-type="bibr">159</xref>,<xref rid="bib165" ref-type="bibr">165</xref>].</p><p id="p0415">Sinopharm (Chinese company) has also carried out Phase 1/2 trials on two inactivated vaccine viruses [<xref rid="bib166" ref-type="bibr">166</xref>]. The vaccine is prepared by inoculating Vero cells with SARS CoV 2 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant. In July, Phase 3 Trial to Assess the Safety and Protective Efficacy of these vaccines in healthy population was started [<xref rid="bib167" ref-type="bibr">167</xref>,<xref rid="bib168" ref-type="bibr">168</xref>]. Recently, the firm announced that its leading vaccine had a 79% efficacy rate in phase 3 trials. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bbc.com/news/world-asia-china-55498197" id="intref0035">https://www.bbc.com/news/world-asia-china-55498197</ext-link>
<underline>.</underline>
</p><p id="p0420">Moreover, some companies are developing live viral vaccines that use cultured SARS-CoV-2 attenuated by passaging. Although strong B and T cell responses may be induced by single administration with no adjuvants, reversion to pathogenicity and disease-causing potential limits these attenuated vaccines [<xref rid="bib169" ref-type="bibr">169</xref>]. Codagenix, Inc. together with the Serum Institute of India, Ltd. are developing a live-attenuated intranasal vaccine against SARS-CoV-2 named COVI-VAC. However, this candidate is still in phase 1 trials to assess its safety and immune response in healthy adults [<xref rid="bib159" ref-type="bibr">159</xref>].</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Subunit vaccines</title><p id="p0425">Subunit vaccines consist of single or numerous strongly immunogenic antigens able to effectively stimulate the immune system. Although this kind of vaccine is harmless and simpler to produce, it demands combining adjuvants to evoke a powerful protective immune response [<xref rid="bib146" ref-type="bibr">146</xref>]. They also require repeated administration, are usually not suitable for respiratory mucosal vaccination and are poor activators of CD8<sup>+</sup> T cell responses [<xref rid="bib162" ref-type="bibr">162</xref>]. Antigens such as E, M, N and S structural proteins are being investigated for subunit vaccine development [<xref rid="bib159" ref-type="bibr">159</xref>].</p><p id="p0430">Several institutions have started developing SARS-CoV-2 subunit vaccine, mainly using the S protein as antigens. For example, Novavax produced a stable nanoparticle vaccine in March 2020. In May, it started a 2-part Phase 1/2 trial of SARS-CoV-2 Recombinant Spike Protein nanoparticle vaccine with or without Matrix-M adjuvant in healthy individuals [<xref rid="bib170" ref-type="bibr">170</xref>]. A phase 3 trial was started in November 2020 to evaluate the effectiveness, immune response, and safety of SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant in the United States, Mexico and UK [<xref rid="bib171" ref-type="bibr">171</xref>].</p><p id="p0435">Virus-like particles (VLPs) are a type of subunit vaccine based on several virus-derived proteins that are collected to imitate the organization of true native viruses but with no viral genome, which makes them safer than attenuated or inactivated preparations [<xref rid="bib162" ref-type="bibr">162</xref>]. These viral proteins are in charge of cell penetration, and therefore efficient cell entry is gained, making them a suitable option when producing a vaccine. VLP vaccines combine sound safety profiles with robust immunogenicity and so are safe alternatives to inactivated viruses. VLPs have outstanding adjuvant properties and are able to stimulate both innate and adaptive immune responses. Experience with formerly developed VLP vaccines showed that they can activate efficient immune responses. These properties make VLPs a superior platform for making vaccines. VLPs are designed using various expression systems, like cells from bacteria, yeast, plants or insects [<xref rid="bib172" ref-type="bibr">172</xref>]. In contrast to subunit vaccines, the array of S protein on the VLP surface crosslinks the B cell receptor and unswervingly stimulates B cells, but, similar to subunit and inactivated vaccines, they necessitate an adjuvant and frequent administration [<xref rid="bib162" ref-type="bibr">162</xref>].</p><p id="p0440">Coronavirus-Like Particle COVID-19 (CoVLP) is a VLP vaccine produced by Medicago, a Canadian company, from genetically engineered plants. Its unpublished results suggest efficacy in inducing neutralizing antibodies in mice [<xref rid="bib173" ref-type="bibr">173</xref>]. It entered phase 3 trials in November to compare the efficacy and safety of the CoVLP formulation to placebo [<xref rid="bib174" ref-type="bibr">174</xref>].</p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>mRNA Vaccines</title><p id="p0445">In this type of vaccine, a synthetic mRNA is inserted into the human body, which acts as instructions for the cells to synthesize that virus&#8217; proteins. Our immune system spots these viral proteins and stimulates an immune response against the virus [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0450">mRNA vaccines are a propitious substitute to traditional vaccines due to their short and low-cost manufacturing cycles, high potency and safety. While no mRNA vaccine has been previously approved for human use, their potential is reinforced by earlier studies of influenza, rabies and Zika virus infections in animals [<xref rid="bib162" ref-type="bibr">162</xref>,<xref rid="bib175" ref-type="bibr">175</xref>]. However, mRNA alone is not very stable to be used as a prophylactic vaccine and are not easily taken up by the cells. Hence it needs lipid nano particle (LNP) carriers which are very effective to stabilize and pack the mRNA into an injectable form [<xref rid="bib176" ref-type="bibr">176</xref>]. They also require cool temperatures to be stored [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0455">An LNP-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the SARS-CoV-2 S protein was the first to start phase I clinical trials in the United States, conducted by Moderna and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate its safety and immunogenicity [<xref rid="bib177" ref-type="bibr">177</xref>]. mRNA-1273 was developed built on earlier studies on SARS-CoV-1 and MERS-CoV. MERS-CoV. Recently published phase 1 results showed that small doses of two parenteral injections are safe and stimulate a primarily CD4<sup>+</sup> T cell response and strong specific antibody responses in tested participants [<xref rid="bib162" ref-type="bibr">162</xref>,<xref rid="bib178" ref-type="bibr">178</xref>]. Moderna started phase 2 trials for its vaccine candidate in May 2020, and in July, a Phase 3 clinical study was started to determine the efficacy, safety, and immunogenicity of mRNA-1273 to prevent infection for up to 2 years after the second dose of mRNA-1273 [<xref rid="bib179" ref-type="bibr">179</xref>]. Clinical trials showed that the Moderna vaccine was 94.1% effective in averting COVID-19 infection in healthy candidates <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html" id="intref0040">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html</ext-link>
<underline>.</underline>
</p><p id="p0460">In addition, the German company BioNTech together with Pfizer and the Chinese drug maker Fosun Pharma also developed an mRNA vaccine, BNT162b2, which is a lipid nanoparticle-formulated vaccine encoding a SARS-CoV-2 S protein. BNT162b2 proved to be 95% effective against Covid-19 and serious adverse events were minimal [<xref rid="bib180" ref-type="bibr">180</xref>].</p></sec><sec id="sec3.2.4"><label>3.2.4</label><title>DNA Vaccines</title><p id="p0465">These are plasmid DNA molecules encoding antigens. DNA vaccine are simple, stable, safe, can be easily and rapidly produced and have been proven to activate both T and B cell responses [<xref rid="bib175" ref-type="bibr">175</xref>]. Moreover, they are superior in delivery efficiency when compared to mRNA vaccines and are heat stable, but they require entry into the nucleus which introduces the threat of vector integration and mutations in the genome of the host [<xref rid="bib181" ref-type="bibr">181</xref>].</p><p id="p0470">Early DNA vaccines had low immunogenicity in humans. However, many strategies have been tried to solve this problem. One such strategy was the use of adaptive electroporation. Transfection efficiency may be improved by up to one thousand fold by membrane electrochemical permeabilization and electric field created by applied voltages which can drastically increase uptake of DNA plasmids into the cells. Further developments have been described in the latest intradermal electroporation (ID-EP) DNA delivery technology. When compared to intramuscular electroporation (IM-EP) DNA delivery, ID-EP was found to be well-tolerated and dose-sparing, particularly in the induction of antibody responses [<xref rid="bib182" ref-type="bibr">182</xref>].</p><p id="p0475">INO-4800, produced by Inovio Pharmaceuticals, is a synthetic DNA vaccine expressing the viral S protein <italic toggle="yes">in vitro</italic>. After intradermal injection (and electroporation (EP) by CELLECTRA&#174; 2000 device) of mice and guinea pigs, specific T cell responses and efficient antibodies which counteract the Covid-19 infection were observed. Moreover, blockage of S protein binding to its receptor and biodistribution of SARS-CoV-2 targeting antibodies to the lungs was reported [<xref rid="bib183" ref-type="bibr">183</xref>]. In June, Phase 1/2 trial was started to assess the vaccine on healthy adult volunteers and in November, Phase 2/3 trial to assess the safety, immunogenicity and efficacy of INO-4800 injected intradermally followed by electroporation in high risk participants was initiated [<xref rid="bib184" ref-type="bibr">184</xref>].</p></sec><sec id="sec3.2.5"><label>3.2.5</label><title>Live vector vaccines</title><p id="p0480">Live viruses may be genetically engineered to serve as vectors and hold pathogenic genes, coding for foreign proteins that evoke immune responses [<xref rid="bib185" ref-type="bibr">185</xref>]. Viral vectors are auspicious tools for gene therapy and vaccines. Live vector vaccines are distinguished by possessing the safety of subunit vaccines and the powerful efficacy of live weakened vaccines [<xref rid="bib146" ref-type="bibr">146</xref>]. They have many advantages including: (a) highly specific delivery of genes to target cells (b) highly efficient gene transduction and (c) stimulation of strong immune responses, and enhanced cellular immunity. Unlike subunit vaccines, which induce a humoral response, recombinant viral vectors allow expression of intracellular antigens and encourage a strong cytotoxic T lymphocyte response [<xref rid="bib186" ref-type="bibr">186</xref>].</p><p id="p0485">The use of viral vectors necessitates a high biological safety level to obtain public approval. Consequently, poorly pathogenic viruses are frequently chosen. Viruses are genetically engineered in most cases to decrease or abolish pathogenicity. Furthermore, most of these vectors are replication-defective [<xref rid="bib186" ref-type="bibr">186</xref>].</p><p id="p0490">Though viral vector platform has been extensively studied and has a well-established track record for infectious diseases, only a few of these vaccines have been accepted for human use. Some viral vectors require one dose for protection and have natural tropism for the respiratory mucosa, making suitable for mucosal vaccination. The expertise for their large-scale clinical grade manufacture and storage already exists, accordingly, they are the second most common platform for COVID-19 vaccine development [<xref rid="bib162" ref-type="bibr">162</xref>].</p><p id="p0495">Delivery systems based on Adenoviruses have many advantages including their simple administration by oral or nasal route and their lack of pathogenicity in humans, especially for non-replicating mutants [<xref rid="bib175" ref-type="bibr">175</xref>]. The Oxford Vaccine Group (which formerly developed a MERS vaccine), and AstraZeneca designed a chimpanzee adenovirus vaccine vector called AZD1222 (formerly ChAdOx1), encoding the S protein. The vaccine proved to be protective in mice, inducing a sturdy humoral and cell-mediated response. It demonstrated a considerably lowered viral load in rhesus macaques after a single vaccination dose, with no evidence of ADE after challenge [<xref rid="bib187" ref-type="bibr">187</xref>].</p><p id="p0500">The AZD1222 vaccine was tested in around 1000 healthy volunteers in April 2020. On 22 May, Oxford researchers declared that they had initiated recruitment for a Phase 2/3 trial of nearly 10,000 healthy adult volunteers to evaluate if individuals of diverse ages could be protected from COVID-19 efficiently [<xref rid="bib188" ref-type="bibr">188</xref>]. In the beginning of June, AstraZeneca announced it had initiated mass production of its potential vaccine and aimed to reach 2 billion doses by September (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html" id="intref0045">https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html</ext-link>). A phase 3 study was started in August [<xref rid="bib159" ref-type="bibr">159</xref>]. However, On 8 September, AstraZeneca stopped clinical trials because of an adverse reaction in one of the tested persons. After a thorough study, the trials recommenced in the U.K., Brazil, South Africa, and India but are still paused in the U.S. as of 23 September [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0505">In addition, the Chinese company CanSino Biologics together with the Institute of Biotechnology, Academy of Military Medical Sciences is designing a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the viral S protein. In March, the safety, tolerability, and efficacy of the vaccine was tested in Phase I trials and proved to be tolerable and protective. Humoral responses culminated at day 28 after vaccination, while quick specific T-cell responses were reported from day 14 post-vaccination in healthy individuals [<xref rid="bib189" ref-type="bibr">189</xref>]. It must be mentioned that these are the first results from Phase I trials of any SARS-CoV-2 vaccine to appear in a scientific journal. Phase 2 clinical trials for the vaccine started last April [<xref rid="bib159" ref-type="bibr">159</xref>]. Results indicated the candidate has a sound safety profile, with no serious adverse events. Single-dose vaccination stimulated quick immune responses within 14 days and substantial humoral and cellular immune responses within 28 days in most cases [<xref rid="bib190" ref-type="bibr">190</xref>]. A global phase 3 trial was initiated in August to assess the efficacy, safety and immunogenicity of the vaccine in individuals. The Chinese government has permitted the vaccine only for military use <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04526990?term=vaccine&amp;cond=covid-19&amp;draw=6" id="intref0050">https://clinicaltrials.gov/ct2/show/NCT04526990?term=vaccine&amp;cond=covid-19&amp;draw=6</ext-link>.</p><p id="p0510">The Chinese government has approved the vaccine for military use only [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0515">As shown in the table, most of the current COVID-19 vaccine are administered parenterally. However, a respiratory mucosal vaccine strategy able to stimulate strong responses straight in the respiratory mucosa will be most efficient in the primary control of the virus. This route is also superior in being needle-free and demanding a much lower dose than the parenteral route. Yet, the need for inhalational devices may be a restrictive factor for extensive application. DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD) is an intranasal vaccine candidate based on Influenza viral vectors and produced by Jiangsu Provincial Center for Disease Prevention and Control. In November 2020, a phase 2 trial to assess the immunogenicity and safety of this vaccine was started [<xref rid="bib191" ref-type="bibr">191</xref>].</p><p id="p0520">It is interesting to note that some SARSCoV-2 vaccine candidates based on viral vectors are being developed to be administered by the oral route. For example, VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine is an oral pill produced by Vaxart (US) and is based on different SARS-CoV-2 antigens [<xref rid="bib192" ref-type="bibr">192</xref>]. However, it is still in Phase 1 trials [<xref rid="bib159" ref-type="bibr">159</xref>].</p></sec><sec id="sec3.2.6"><label>3.2.6</label><title>Nonspecific vaccines</title><p id="p0525">Vaccines already protective against other infections may also be used against COVID-19. The Murdoch Children's Research Institute in Australia is running a Phase 3 trial on the BCG vaccine (developed in the early 1900s against tuberculosis), and numerous other tests are in progress to check if this vaccine confers any protection against SARS-CoV-2 [<xref rid="bib193" ref-type="bibr">193</xref>]. Recently, BCG vaccine has been suggested to prevent SARS-CoV-2 infection, due to its potential to lift up innate immunity and preliminary epidemiological studies which detected decreased COVID-19 severity in nations with universal BCG vaccination guidelines. However, these studies were not systematically corrected for confounding variables. In October 2020, Hansel et al. reported that, after correction for confounding variables, their epidemiological results do not provide evidence to link overall BCG vaccination policy with the spread and mortality of covid-19 [<xref rid="bib194" ref-type="bibr">194</xref>].</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Concluding remarks</title><p id="p0530">The COVID-19 outbreak, due to its rapid spread, has affected our daily lives in every way. When we will fully mend from these effects and whether normal life will ever return is still unknown. During the past months, a lot has been learned about this disease and its causative virus. Therefore, here, we reviewed the updated advances about diverse aspects including clinical features, source of infection, transmission dynamics, genomic characterization and uncovering of novel approaches for disease control. Yet, there are still many knowledge gaps around many aspects including the differences in susceptibility, progression, and outcome of the infection by SARS-CoV-2 which, undoubtedly relies on a multifaceted interaction of human body, the virus and environmental influences. Also, there is no definite and highly effective treatment yet. All these topics need to be further researched quickly to reach successful outcomes and happy endings.</p><p id="p0535">Coronaviruses are genetically dissimilar and have a great predisposition to recurrent genetic mutations. These mutations have clearly been central for the virus evolutionary history, and unfortunately, may well result in other analogous epidemic outbreaks in the coming years. Accordingly, in addition to restricting this epidemic, we should work hard to develop complete measures to avert upcoming outbursts of zoonotic basis.</p><p id="p0540">Considering the strong influence of this pandemic on economies worldwide, funding a vaccine producing framework that would permit a quick reaction to upcoming infections is indeed a huge investment. This will generate satisfactory and ready vaccine candidates that can be used swiftly and effectively to stop an emerging infection immediately. Smart emergency strategies that help us to check, manufacture and spread vaccines within months is also urgently needed. Hopefully, many lessons will be gained from this pandemic which will render us ready in the future.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0545">The authors declare no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>Coronavirus Disease (COVID-19) Situation Report&#8211;135</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135pdf?sfvrsn=39972feb_2" id="intref0055">https://wwwwhoint/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135pdf?sfvrsn=39972feb_2</ext-link><comment>accessed</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>Emergencies Preparedness, Response</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/" id="intref0060">https://wwwwhoint/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/</ext-link><comment>accessed</comment></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Worobey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pekar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suchard</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wertheim</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P.</given-names></name></person-group><article-title>The emergence of SARS-CoV-2 in Europe and North America</article-title><source>Science</source><volume>370</volume><year>2020</year><fpage>564</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1126/science.abc8169</pub-id><pub-id pub-id-type="pmid">32912998</pub-id><pub-id pub-id-type="pmcid">PMC7810038</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Apolone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Montomoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Manenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boeri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hyseni</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mazzini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinuzzi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cantone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Milanese</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sestini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suatoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marchian&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bollati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sozzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>U.</given-names></name></person-group><article-title>Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy</article-title><source>Tumori Journal</source><year>2020</year><pub-id pub-id-type="doi">10.1177/0300891620974755</pub-id><pub-id pub-id-type="pmcid">PMC8529295</pub-id><pub-id pub-id-type="pmid">33176598</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="book" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>COVID-19 Public Health Emergency of International Concern (PHEIC) Global Research and Innovation Forum</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum" id="intref0065">https://wwwwhoint/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum</ext-link><comment>accessed July 2020</comment></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Gorbalenya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gulyaeva A</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol<italic toggle="yes">.</italic></source><volume>5</volume><year>2020</year><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="book" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 February 2020</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020" id="intref0070">https://wwwwhoint/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020</ext-link><comment>accessed July 2020</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="book" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>WHO Director-General's Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020" id="intref0075">https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link><comment>accessed July 2020</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="book" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>Coronavirus Disease (COVID-19) Weekly Epidemiological Update</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/weekly-epidemiological-update" id="intref0080">https://www.who.int/publications/m/item/weekly-epidemiological-update</ext-link><comment>accessed</comment></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="book" id="sref11"><person-group person-group-type="author"><collab>NCBI</collab></person-group><part-title>Severe Acute Respiratory Syndrome Coronavirus 2</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwncbinlmnihgov/Taxonomy/Browser/wwwtaxcgi?id=2697049" id="intref0085">https://wwwncbinlmnihgov/Taxonomy/Browser/wwwtaxcgi?id=2697049</ext-link><comment>accessed</comment></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.E.</given-names></name></person-group><article-title>Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)</article-title><source>Clin. Exp. Pediatr.</source><volume>63</volume><year>2020</year><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.3345/cep.2020.00493</pub-id><pub-id pub-id-type="pmid">32252141</pub-id><pub-id pub-id-type="pmcid">PMC7170784</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Zaki</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van Boheemen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>W.</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brodt</surname><given-names>H.-R.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N. Engl. J. Med.</source><volume>348</volume><year>2003</year><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030747</pub-id><pub-id pub-id-type="pmid">12690091</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment</article-title><source>Int. J. Antimicrob. Agents</source><volume>55</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105950</pub-id><comment>105950-105950</comment><pub-id pub-id-type="pmcid">PMC7118423</pub-id><pub-id pub-id-type="pmid">32234465</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.-W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.-W.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id><pub-id pub-id-type="pmid">31986261</pub-id><pub-id pub-id-type="pmcid">PMC7159286</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="other" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><article-title>Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations" id="intref0090">https://wwwwhoint/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations</ext-link><year>2020</year><comment>accessed</comment></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>A.B.</given-names></name></person-group><article-title>Efforts at COVID-19 vaccine development: challenges and successes</article-title><source>Vaccines</source><volume>8</volume><year>2020</year><fpage>739</fpage><pub-id pub-id-type="doi">10.3390/vaccines8040739</pub-id><pub-id pub-id-type="pmid">33291245</pub-id><pub-id pub-id-type="pmcid">PMC7762169</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>S.W.X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.S.Y.</given-names></name><etal/></person-group><article-title>Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient</article-title><source>J. Am. Med. Assoc.</source><volume>323</volume><year>2020</year><fpage>1610</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.3227</pub-id><pub-id pub-id-type="pmcid">PMC7057172</pub-id><pub-id pub-id-type="pmid">32129805</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Pastorino</surname><given-names>B.</given-names></name><name name-style="western"><surname>Touret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gilles</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Charrel</surname><given-names>R.N.</given-names></name></person-group><article-title>Prolonged infectivity of SARS-CoV-2 in fomites, emerg</article-title><source>Inf. Disp.</source><volume>26</volume><year>2020</year><fpage>2256</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.3201/eid2609.201788</pub-id><pub-id pub-id-type="pmcid">PMC7454106</pub-id><pub-id pub-id-type="pmid">32579874</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Riddell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eagles</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>T.W.</given-names></name></person-group><article-title>The effect of temperature on persistence of SARS-CoV-2 on common surfaces</article-title><source>Virol. J.</source><volume>17</volume><year>2020</year><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s12985-020-01418-7</pub-id><pub-id pub-id-type="pmid">33028356</pub-id><pub-id pub-id-type="pmcid">PMC7538848</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Mondelli</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Colaneri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seminari</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Baldanti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name></person-group><article-title>Low risk of SARS-CoV-2 transmission by fomites in real-life conditions</article-title><source>Lancet Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30678-2</pub-id><pub-id pub-id-type="pmcid">PMC7524520</pub-id><pub-id pub-id-type="pmid">33007224</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>S.W.X.</given-names></name><name name-style="western"><surname>Kalimuddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Low</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Loh J</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore</article-title><source>J. Am. Med. Assoc.</source><volume>323</volume><year>2020</year><fpage>1488</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.3204</pub-id><pub-id pub-id-type="pmcid">PMC7054855</pub-id><pub-id pub-id-type="pmid">32125362</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Public health might be endangered by possible prolonged discharge of SARS-CoV-2 in stool</article-title><source>J. Infect.</source><volume>80</volume><year>2020</year><fpage>e18</fpage><lpage>e19</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.031</pub-id><pub-id pub-id-type="pmid">32145217</pub-id><pub-id pub-id-type="pmcid">PMC7133677</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30360-3</pub-id><pub-id pub-id-type="pmid">32151335</pub-id><pub-id pub-id-type="pmcid">PMC7159281</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Antibodies in infants born to mothers with COVID-19 pneumonia</article-title><source>J. Am. Med. Assoc.</source><volume>323</volume><year>2020</year><fpage>1848</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4861</pub-id><pub-id pub-id-type="pmcid">PMC7099444</pub-id><pub-id pub-id-type="pmid">32215589</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kalafat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Benlioglu</surname><given-names>C.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Draycott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thangaratinam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Le Doare</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ladhani</surname><given-names>S.</given-names></name><name name-style="western"><surname>von Dadelszen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Magee</surname><given-names>L.A.</given-names></name></person-group><article-title>SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes</article-title><source>EClinicalMedicine</source><volume>25</volume><year>2020</year><fpage>100446</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100446</pub-id><pub-id pub-id-type="pmid">32838230</pub-id><pub-id pub-id-type="pmcid">PMC7334039</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>W-j.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z-y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W-h.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>C-q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J-x.</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="other" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><article-title>Coronavirus symptoms</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/health-topics/coronavirus#tab=tab_3" id="intref0095">https://wwwwhoint/health-topics/coronavirus#tab=tab_3</ext-link><year>2020</year><comment>accessed</comment></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Gelardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trecca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciprandi</surname><given-names>G.</given-names></name></person-group><article-title>Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report</article-title><source>Acta Bio Medica Atenei Parmensis</source><volume>91</volume><year>2020</year><fpage>230</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.23750/abm.v91i2.9524</pub-id><pub-id pub-id-type="pmcid">PMC7569643</pub-id><pub-id pub-id-type="pmid">32420954</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.-F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.-P.</given-names></name><etal/></person-group><article-title>Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province</article-title><source>Chin. Med. J.</source><volume>133</volume><year>2020</year><pub-id pub-id-type="doi">10.1097/CM9.0000000000000744</pub-id><pub-id pub-id-type="pmcid">PMC7147277</pub-id><pub-id pub-id-type="pmid">32044814</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</article-title><source>Sci. China Life Sci.</source><volume>63</volume><year>2020</year><fpage>364</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1007/s11427-020-1643-8</pub-id><pub-id pub-id-type="pmid">32048163</pub-id><pub-id pub-id-type="pmcid">PMC7088566</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#8211;infected pneumonia in wuhan, China</article-title><source>J. Am. Med. Assoc.</source><volume>323</volume><year>2020</year><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id><pub-id pub-id-type="pmid">32031570</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="book" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>Coronavirus Disease (COVID-19) Technical Guidance: Laboratory Testing for 2019-nCoV in Humans</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwwhoint/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance" id="intref0100">https://wwwwhoint/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance</ext-link><comment>accessed</comment></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Harman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Radia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deep</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Ethnicity and COVID-19 in children with comorbidities</article-title><source>Lancet Child Adolesc. Health.</source><volume>4</volume><year>2020</year><fpage>e24</fpage><lpage>e25</lpage><pub-id pub-id-type="doi">10.1016/S2352-4642(20)30167-X</pub-id><pub-id pub-id-type="pmid">32473663</pub-id><pub-id pub-id-type="pmcid">PMC7255990</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Rothe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schunk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sothmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bretzel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Froeschl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wallrauch</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>970</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001468</pub-id><pub-id pub-id-type="pmid">32003551</pub-id><pub-id pub-id-type="pmcid">PMC7120970</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name></person-group><article-title>Nidovirales: evolving the largest RNA virus genome</article-title><source>Virus Res.</source><volume>117</volume><year>2006</year><fpage>17</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2006.01.017</pub-id><pub-id pub-id-type="pmid">16503362</pub-id><pub-id pub-id-type="pmcid">PMC7114179</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>A.C.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol.</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id><pub-id pub-id-type="pmcid">PMC7125511</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Ann. Rev. Virol.</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.-R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.-D.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z.-S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.-J.</given-names></name><etal/></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak &#8211; an update on the status</article-title><source>Mil. Med. Res.</source><volume>7</volume><year>2020</year><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s40779-020-00240-0</pub-id><pub-id pub-id-type="pmid">32169119</pub-id><pub-id pub-id-type="pmcid">PMC7068984</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol. Biol.</source><volume>1282</volume><year>2015</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmid">25720466</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kunding</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Bhella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baksh</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A structural analysis of M protein in coronavirus assembly and morphology</article-title><source>J. Struct. Biol.</source><volume>174</volume><year>2011</year><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2010.11.021</pub-id><pub-id pub-id-type="pmid">21130884</pub-id><pub-id pub-id-type="pmcid">PMC4486061</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Schoeman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>B.C.</given-names></name></person-group><article-title>Coronavirus envelope protein: current knowledge</article-title><source>Virology</source><volume>16</volume><year>2019</year><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id><pub-id pub-id-type="pmid">31133031</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The establishment of reference sequence for SARS-CoV-2 and variation analysis</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1002/jmv.25762</pub-id><pub-id pub-id-type="pmid">32167180</pub-id><pub-id pub-id-type="pmcid">PMC7228400</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microb. Infect.</source><volume>9</volume><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmcid">PMC7067204</pub-id><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</article-title><source>Cell Host Microbe</source><volume>27</volume><year>2020</year><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id><pub-id pub-id-type="pmid">32035028</pub-id><pub-id pub-id-type="pmcid">PMC7154514</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Vemula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Donde</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gouda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Behera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vadde</surname><given-names>R.</given-names></name></person-group><article-title>In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1751300</pub-id><pub-id pub-id-type="pmcid">PMC7171389</pub-id><pub-id pub-id-type="pmid">32238078</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yarmishyn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A review of sars-cov-2 and the ongoing clinical trials</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>2657</fpage><pub-id pub-id-type="doi">10.3390/ijms21072657</pub-id><pub-id pub-id-type="pmid">32290293</pub-id><pub-id pub-id-type="pmcid">PMC7177898</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Angeletti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pascarella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><article-title>COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>584</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1002/jmv.25719</pub-id><pub-id pub-id-type="pmid">32083328</pub-id><pub-id pub-id-type="pmcid">PMC7228367</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Khailany</surname><given-names>R.</given-names></name><name name-style="western"><surname>Safdar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozaslan</surname><given-names>M.</given-names></name></person-group><article-title>Genomic characterization of a novel SARS-CoV-2</article-title><source>Gene Rep</source><volume>19</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.genrep.2020.100682</pub-id><pub-id pub-id-type="pmcid">PMC7161481</pub-id><pub-id pub-id-type="pmid">32300673</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Koyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Platt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>L.</given-names></name></person-group><article-title>Variant analysis of SARS-CoV-2 genomes</article-title><source>Bull. World Health Organ.</source><volume>98</volume><year>2020</year><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.2471/BLT.20.253591</pub-id><pub-id pub-id-type="pmid">32742035</pub-id><pub-id pub-id-type="pmcid">PMC7375210</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Bal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Destras</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaymard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouscambert-Duchamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Escuret</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino-acid deletion in nsp2 (Asp268Del)</article-title><source>Clin. Microbiol. Infect.</source><volume>26</volume><year>2020</year><fpage>960</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.020</pub-id><pub-id pub-id-type="pmid">32234449</pub-id><pub-id pub-id-type="pmcid">PMC7142683</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M.</given-names></name></person-group><article-title>SARS coronavirus replicase proteins in pathogenesis</article-title><source>Virus Res.</source><volume>133</volume><year>2008</year><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.017</pub-id><pub-id pub-id-type="pmid">17397959</pub-id><pub-id pub-id-type="pmcid">PMC2637536</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Totura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.</given-names></name></person-group><article-title>SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon</article-title><source>Curr. Opin. Virol.</source><volume>2</volume><year>2012</year><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2012.04.004</pub-id><pub-id pub-id-type="pmid">22572391</pub-id><pub-id pub-id-type="pmcid">PMC7102726</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Jauregui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Savalia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lowry</surname><given-names>V.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wathelet</surname><given-names>M.</given-names></name></person-group><article-title>Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling</article-title><source>PloS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e62416</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0062416</pub-id><pub-id pub-id-type="pmcid">PMC3639174</pub-id><pub-id pub-id-type="pmid">23658627</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Cornillez-Ty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buchmeier</surname><given-names>M.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling</article-title><source>J. Virol.</source><volume>83</volume><year>2009</year><fpage>10314</fpage><lpage>10318</lpage><pub-id pub-id-type="doi">10.1128/jvi.00842-09</pub-id><pub-id pub-id-type="pmid">19640993</pub-id><pub-id pub-id-type="pmcid">PMC2748024</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Oostra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hagemeijer</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Gent</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>C.</given-names></name><name name-style="western"><surname>te Lintelo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning</article-title><source>J. Virol.</source><volume>82</volume><year>2008</year><fpage>12392</fpage><lpage>12405</lpage><pub-id pub-id-type="doi">10.1128/jvi.01219-08</pub-id><pub-id pub-id-type="pmid">18842706</pub-id><pub-id pub-id-type="pmcid">PMC2593338</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Shankar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhanu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alluri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Whole genome sequence analysis and homology modelling of main protease and non-structural protein 3 of the SARS-CoV-2 reveals an aza-peptide and a lead inhibitor with possible antiviral properties</article-title><source>New J. Chem.</source><volume>44</volume><year>2020</year><fpage>9202</fpage><lpage>9212</lpage><pub-id pub-id-type="doi">10.1039/d0nj00974a</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Sakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Omori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kamitani</surname><given-names>W.</given-names></name></person-group><article-title>Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication</article-title><source>Virology</source><volume>510</volume><year>2017</year><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.07.019</pub-id><pub-id pub-id-type="pmid">28738245</pub-id><pub-id pub-id-type="pmcid">PMC7111695</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Snijder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Decroly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>The nonstructural proteins directing coronavirus RNA synthesis and processing</article-title><source>Adv. Virus Res.</source><volume>96</volume><year>2016</year><fpage>59</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.008</pub-id><pub-id pub-id-type="pmid">27712628</pub-id><pub-id pub-id-type="pmcid">PMC7112286</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Structure of Mpro from COVID-19 virus and discovery of its inhibitors</article-title><source>Nature</source><volume>582</volume><year>2020</year><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bartlam</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer</article-title><source>Nat. Struct. Mol. Biol.</source><volume>12</volume><year>2005</year><fpage>980</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1038/nsmb999</pub-id><pub-id pub-id-type="pmid">16228002</pub-id><pub-id pub-id-type="pmcid">PMC7096913</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Egloff</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Ferron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campanacci</surname><given-names>V.</given-names></name><etal/></person-group><article-title>The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>101</volume><year>2004</year><fpage>3792</fpage><lpage>3796</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307877101</pub-id><pub-id pub-id-type="pmid">15007178</pub-id><pub-id pub-id-type="pmcid">PMC374323</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Posthuma</surname><given-names>C.</given-names></name><name name-style="western"><surname>te Velthuis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.</given-names></name></person-group><article-title>Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes</article-title><source>Virus Res.</source><volume>234</volume><year>2017</year><fpage>58</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.01.023</pub-id><pub-id pub-id-type="pmid">28174054</pub-id><pub-id pub-id-type="pmcid">PMC7114556</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sp</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name></person-group><article-title>A high ATP concentration enhances the cooperative translocation of the SARS coronavirus helicase nsP13 in the unwinding of duplex RNA</article-title><source>Sci. Rep.</source><volume>10</volume><year>2020</year><fpage>4481</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-61432-1</pub-id><pub-id pub-id-type="pmid">32161317</pub-id><pub-id pub-id-type="pmcid">PMC7066239</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>On the origin and continuing evolution of SARS-CoV-2</article-title><source>Natl. Sci. Rev.</source><volume>nwaa036</volume><year>2020</year><pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id><pub-id pub-id-type="pmcid">PMC7107875</pub-id><pub-id pub-id-type="pmid">34676127</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="book" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>COVID-19 Disease Outbreak News. SARS-CoV-2 Mink Associated Variant Strain- Denmark</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/" id="intref0105">https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/</ext-link><comment>accessed January 2021</comment></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="book" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Lassauni&#232;re</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fonager</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frische</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frische</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>B&#248;tner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fomsgaard</surname><given-names>A.</given-names></name></person-group><part-title>SARS-CoV-2 Spike Mutations Arising in Danish Mink and Their Spread to Humans</part-title><year>2020</year><publisher-name>Preprint</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://files.ssi.dk/Mink-cluster-5-short-report_AFO2" id="intref0110">https://files.ssi.dk/Mink-cluster-5-short-report_AFO2</ext-link></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="book" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><part-title>COVID-19 Disease Outbreak News. SARS-CoV-2 Variant- United Kingdom of Great Britain and Northern Ireland</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/" id="intref0115">https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/</ext-link><comment>accessed January 2021</comment></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V.</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>T.R.</given-names></name></person-group><article-title>Evaluating the effects of SARS-CoV-2 spike mutation D614G on Transmissibility and pathogenicity</article-title><source>Cell</source><volume>184</volume><year>2021</year><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.020</pub-id><pub-id pub-id-type="pmid">33275900</pub-id><pub-id pub-id-type="pmcid">PMC7674007</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeletti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pascarella</surname><given-names>S.</given-names></name></person-group><article-title>Sars-CoV-2 envelope and membrane proteins: structural differences linked to virus characteristics?</article-title><source>BioMed Res. Int.</source><year>2020</year><pub-id pub-id-type="doi">10.1155/2020/4389089</pub-id><pub-id pub-id-type="pmcid">PMC7261327</pub-id><pub-id pub-id-type="pmid">32596311</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Venkatagopalan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Daskalova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dolezal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hogue</surname><given-names>B.</given-names></name></person-group><article-title>Coronavirus envelope (E) protein remains at the site of assembly</article-title><source>Virology</source><volume>478</volume><year>2015</year><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.02.005</pub-id><pub-id pub-id-type="pmid">25726972</pub-id><pub-id pub-id-type="pmcid">PMC4550588</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Identifying SARS-CoV membrane protein amino acid residues linked to virus-like particle assembly</article-title><source>PloS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e64013</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0064013</pub-id><pub-id pub-id-type="pmcid">PMC3659117</pub-id><pub-id pub-id-type="pmid">23700447</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nabar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kehrl</surname><given-names>J.</given-names></name></person-group><article-title>SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes</article-title><source>Cell Death Dis.</source><volume>5</volume><year>2019</year><fpage>101</fpage><pub-id pub-id-type="doi">10.1038/s41420-019-0181-7</pub-id><pub-id pub-id-type="pmcid">PMC6549181</pub-id><pub-id pub-id-type="pmid">31231549</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Modular organization of SARS coronavirus nucleocapsid protein</article-title><source>J. Biomed. Sci.</source><volume>13</volume><year>2006</year><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s11373-005-9035-9</pub-id><pub-id pub-id-type="pmid">16228284</pub-id><pub-id pub-id-type="pmcid">PMC7089556</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Hurst</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koetzner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>P.</given-names></name></person-group><article-title>Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein</article-title><source>J. Virol.</source><volume>83</volume><year>2009</year><fpage>7221</fpage><lpage>7234</lpage><pub-id pub-id-type="doi">10.1128/jvi.00440-09</pub-id><pub-id pub-id-type="pmid">19420077</pub-id><pub-id pub-id-type="pmcid">PMC2704785</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Zyl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>B.</given-names></name></person-group><article-title>The coronavirus nucleocapsid is a multifunctional protein</article-title><source>Viruses</source><volume>6</volume><year>2014</year><fpage>2991</fpage><lpage>3018</lpage><pub-id pub-id-type="doi">10.3390/v6082991</pub-id><pub-id pub-id-type="pmid">25105276</pub-id><pub-id pub-id-type="pmcid">PMC4147684</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites</article-title><source>Acta Pharm. Sin. B</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.009</pub-id><pub-id pub-id-type="pmcid">PMC7194921</pub-id><pub-id pub-id-type="pmid">32363136</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein</article-title><source>Curr. Biol.</source><volume>30</volume><year>2020</year><fpage>2196</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2020.05.023</pub-id><pub-id pub-id-type="pmid">32416074</pub-id><pub-id pub-id-type="pmcid">PMC7211627</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R.</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shum</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2169-0</pub-id><pub-id pub-id-type="pmid">32218527</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.035</pub-id><pub-id pub-id-type="pmid">32220310</pub-id><pub-id pub-id-type="pmcid">PMC7194821</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>G.</given-names></name></person-group><article-title>Pangolins harbor SARS-CoV-2-related coronaviruses</article-title><source>Trends Microbiol.</source><volume>28</volume><year>2020</year><fpage>515</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2020.04.001</pub-id><pub-id pub-id-type="pmid">32544437</pub-id><pub-id pub-id-type="pmcid">PMC7136945</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.-Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X.-F.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?</article-title><source>PLoS Pathog.</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008421</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008421</pub-id><pub-id pub-id-type="pmcid">PMC7224457</pub-id><pub-id pub-id-type="pmid">32407364</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1002/jmv.25726</pub-id><pub-id pub-id-type="pmid">32100877</pub-id><pub-id pub-id-type="pmcid">PMC7228221</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1</article-title><source>J. Proteome Res.</source><volume>19</volume><year>2020</year><fpage>1351</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00129</pub-id><pub-id pub-id-type="pmid">32200634</pub-id><pub-id pub-id-type="pmcid">PMC7099673</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Genomic characterisation andepidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Genotyping coronavirus SARS-CoV-2: methods and implications</article-title><source>Genomics</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ygeno.2020.04.016</pub-id><pub-id pub-id-type="pmcid">PMC7184998</pub-id><pub-id pub-id-type="pmid">32353474</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Boopathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poma</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group><article-title>Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1758788</pub-id><pub-id pub-id-type="pmcid">PMC7196923</pub-id><pub-id pub-id-type="pmid">32306836</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>1620</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id><pub-id pub-id-type="pmcid">PMC7100515</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name></person-group><article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>894</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmid">32275855</pub-id><pub-id pub-id-type="pmcid">PMC7144619</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><comment>e8</comment><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Brielle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name><name name-style="western"><surname>Linial</surname><given-names>M.</given-names></name></person-group><article-title>The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor</article-title><source>Viruses</source><volume>12</volume><year>2020</year><pub-id pub-id-type="doi">10.3390/v12050497</pub-id><pub-id pub-id-type="pmcid">PMC7291053</pub-id><pub-id pub-id-type="pmid">32365751</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway</article-title><source>Cell Res.</source><volume>18</volume><year>2008</year><fpage>290</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.15</pub-id><pub-id pub-id-type="pmid">18227861</pub-id><pub-id pub-id-type="pmcid">PMC7091891</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Gerasimenko</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Tepikin</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Gerasimenko</surname><given-names>O.V.</given-names></name></person-group><article-title>Calcium uptake via endocytosis with rapid release from acidifying endosomes</article-title><source>Curr. Biol.</source><volume>8</volume><year>1998</year><fpage>1335</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(07)00565-9</pub-id><pub-id pub-id-type="pmid">9843688</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Masters</surname><given-names>P.</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source>Adv. Virus Res.</source><volume>66</volume><year>2006</year><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id><pub-id pub-id-type="pmid">16877062</pub-id><pub-id pub-id-type="pmcid">PMC7112330</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N.M.A.</given-names></name><name name-style="western"><surname>van Haperen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><etal/></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>2251</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16256-y</pub-id><pub-id pub-id-type="pmid">32366817</pub-id><pub-id pub-id-type="pmcid">PMC7198537</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Ortega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pujol</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>H.</given-names></name></person-group><article-title>Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis</article-title><source>EXCLI J</source><volume>19</volume><year>2020</year><fpage>410</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.17179/excli2020-1167</pub-id><pub-id pub-id-type="pmid">32210742</pub-id><pub-id pub-id-type="pmcid">PMC7081066</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.J.</given-names></name></person-group><article-title>Structure analysis of the receptor binding of 2019-nCoV</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>525</volume><year>2020</year><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.071</pub-id><pub-id pub-id-type="pmid">32081428</pub-id><pub-id pub-id-type="pmcid">PMC7092824</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dorfman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>10628</fpage><lpage>10635</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.19.10628-10635.2004</pub-id><pub-id pub-id-type="pmid">15367630</pub-id><pub-id pub-id-type="pmcid">PMC516384</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Cava</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bertoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Castiglioni</surname><given-names>I.</given-names></name></person-group><article-title>In silico discovery of candidate drugs against covid-19</article-title><source>Viruses</source><volume>12</volume><year>2020</year><pub-id pub-id-type="doi">10.3390/v12040404</pub-id><pub-id pub-id-type="pmcid">PMC7232366</pub-id><pub-id pub-id-type="pmid">32268515</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Almaz&#225;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Z&#250;&#241;iga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Continuous and discontinuous RNA synthesis in coronaviruses</article-title><source>Annu Rev Virol</source><volume>2</volume><year>2015</year><fpage>265</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-100114-055218</pub-id><pub-id pub-id-type="pmid">26958916</pub-id><pub-id pub-id-type="pmcid">PMC6025776</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Harcourt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jukneliene</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kanjanahaluethai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bechill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Severson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.24.13600&amp;#x02013;13612.2004</pub-id><comment>13600&#8211;12</comment><pub-id pub-id-type="pmcid">PMC533933</pub-id><pub-id pub-id-type="pmid">15564471</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title><source>Acta Pharm. Sin. B</source><volume>10</volume><year>2020</year><fpage>766</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">32292689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.02.008</pub-id><pub-id pub-id-type="pmcid">PMC7102550</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Pachetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Benedetti</surname><given-names>F.</given-names></name></person-group><article-title>Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant</article-title><source>J. Transl. Med.</source><volume>18</volume><year>2020</year><pub-id pub-id-type="doi">10.1186/s12967-020-02344-6</pub-id><pub-id pub-id-type="pmcid">PMC7174922</pub-id><pub-id pub-id-type="pmid">32321524</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>De Haan</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Vennema</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.J.M.</given-names></name></person-group><article-title>Assembly of the coronavirus envelope: homotypic interactions between the M proteins</article-title><source>J. Virol.</source><volume>74</volume><year>2000</year><fpage>4967</fpage><pub-id pub-id-type="doi">10.1128/JVI.74.11.4967-4978.2000</pub-id><pub-id pub-id-type="pmid">10799570</pub-id><pub-id pub-id-type="pmcid">PMC110848</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>De Haan</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.J.M.</given-names></name></person-group><article-title>Molecular interactions in the assembly of coronaviruses</article-title><source>Adv. Virus Res.</source><volume>64</volume><year>2005</year><fpage>165</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">16139595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0065-3527(05)64006-7</pub-id><pub-id pub-id-type="pmcid">PMC7112327</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>P.-K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.-T.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Y.-H.</given-names></name><etal/></person-group><article-title>Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>13848</fpage><lpage>13855</lpage><pub-id pub-id-type="doi">10.1128/jvi.79.22.13848-13855.2005</pub-id><pub-id pub-id-type="pmid">16254320</pub-id><pub-id pub-id-type="pmcid">PMC1280188</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Surjit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S.</given-names></name></person-group><article-title>The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells</article-title><source>J. Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>10669</fpage><lpage>10681</lpage><pub-id pub-id-type="doi">10.1074/jbc.M509233200</pub-id><pub-id pub-id-type="pmid">16431923</pub-id><pub-id pub-id-type="pmcid">PMC7995956</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Siu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F.</given-names></name><name name-style="western"><surname>Escriou</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles</article-title><source>J. Virol.</source><volume>82</volume><year>2008</year><fpage>11318</fpage><lpage>11330</lpage><pub-id pub-id-type="doi">10.1128/JVI.01052-08</pub-id><pub-id pub-id-type="pmid">18753196</pub-id><pub-id pub-id-type="pmcid">PMC2573274</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Pervushin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Parthasarathy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu D</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Structure and inhibition of the SARS coronavirus envelope protein ion channel</article-title><source>PLoS Pathog.</source><volume>5</volume><year>2009</year><object-id pub-id-type="publisher-id">e1000511</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000511</pub-id><pub-id pub-id-type="pmcid">PMC2702000</pub-id><pub-id pub-id-type="pmid">19593379</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name></person-group><article-title>Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking</article-title><source>Int. J. Antimicrob. Agents</source><volume>56</volume><year>2020</year><fpage>106012</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106012</pub-id><pub-id pub-id-type="pmid">32389723</pub-id><pub-id pub-id-type="pmcid">PMC7205718</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Mothay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>K.</given-names></name></person-group><article-title>Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock</article-title><source>Virus (Tokyo)</source><volume>31</volume><year>2020</year><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s13337-020-00585-z</pub-id><pub-id pub-id-type="pmcid">PMC7195910</pub-id><pub-id pub-id-type="pmid">32363219</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Muralidharan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sakthivel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Velmurugan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gromiha</surname><given-names>M.M.</given-names></name></person-group><article-title>Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonvir binding with SARS-COV-2 against COVID-19</article-title><source>J. Biomol. Struct. Dyn.</source><volume>16</volume><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1752802</pub-id><pub-id pub-id-type="pmid">32248766</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Huynh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>B.</given-names></name></person-group><article-title>In silico exploration of molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2&#8217;s main protease</article-title><source>J. Phys. Chem. Lett.</source><volume>11</volume><year>2020</year><fpage>4413</fpage><lpage>4420</lpage><pub-id pub-id-type="doi">10.1021/acs.jpclett.0c00994</pub-id><pub-id pub-id-type="pmid">32406687</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><etal/></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><pub-id pub-id-type="pmcid">PMC7108130</pub-id><pub-id pub-id-type="pmid">32150618</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Andreani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Bideau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duflot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jardot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boxberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wurtz</surname><given-names>N.</given-names></name><name name-style="western"><surname>M Rolain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Colson</surname><given-names>P.</given-names></name><name name-style="western"><surname>La Scola</surname><given-names>B.</given-names></name><etal/></person-group><article-title>In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect</article-title><source>Microb. Pathog.</source><volume>145</volume><year>2020</year><fpage>104</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104228</pub-id><pub-id pub-id-type="pmcid">PMC7182748</pub-id><pub-id pub-id-type="pmid">32344177</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Kalra</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Tomar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Meena</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kandimalla</surname><given-names>R.</given-names></name></person-group><article-title>SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings</article-title><source>Pathogens</source><volume>9</volume><year>2020</year><fpage>546</fpage><pub-id pub-id-type="doi">10.3390/pathogens9070546</pub-id><pub-id pub-id-type="pmid">32645974</pub-id><pub-id pub-id-type="pmcid">PMC7400328</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title><source>Cell Discov</source><volume>6</volume><year>2020</year><pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><comment>14&#8211;14</comment><pub-id pub-id-type="pmcid">PMC7073332</pub-id><pub-id pub-id-type="pmid">32194980</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Ul Qamar</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Alamri</surname><given-names>M.A.</given-names></name><collab>LL. Chen LL</collab></person-group><article-title>Structural basis of SARS-CoV-2 3CL<sup>pro</sup> and anti-COVID-19 drug discovery from medicinal plants</article-title><source>J Pharm Anal</source><volume>10</volume><year>2020</year><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><pub-id pub-id-type="pmid">32296570</pub-id><pub-id pub-id-type="pmcid">PMC7156227</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Abdelli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hassani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bekkel Brikci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghalem</surname><given-names>S.</given-names></name></person-group><article-title>In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1763199</pub-id><pub-id pub-id-type="pmcid">PMC7232889</pub-id><pub-id pub-id-type="pmid">32362217</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name></person-group><article-title>In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>24</volume><year>2020</year><fpage>4529&#8208;4536</fpage><pub-id pub-id-type="doi">10.26355/eurrev_202004_21036</pub-id><pub-id pub-id-type="pmid">32373991</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa224</pub-id><pub-id pub-id-type="pmcid">PMC7184403</pub-id><pub-id pub-id-type="pmid">32239142</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kr&#225;l</surname><given-names>P.</given-names></name></person-group><article-title>Computational design of ACE2-based peptide inhibitors of SARS-CoV-2</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>5143</fpage><lpage>5147</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c02857</pub-id><pub-id pub-id-type="pmid">32286790</pub-id><pub-id pub-id-type="pmcid">PMC7163933</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Lythgoe</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>P.</given-names></name></person-group><article-title>Ongoing clinical trials for the management of the COVID-19 pandemic</article-title><source>Trends Pharmacol. Sci.</source><volume>41</volume><year>2020</year><fpage>363</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.03.006</pub-id><pub-id pub-id-type="pmid">32291112</pub-id><pub-id pub-id-type="pmcid">PMC7144665</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><comment>1787&#8211;99</comment><pub-id pub-id-type="pmcid">PMC7121492</pub-id><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Gurwitz</surname><given-names>D.</given-names></name></person-group><article-title>Angiotensin receptor blockers as tentative SARS&#8208;CoV&#8208;2 therapeutics</article-title><source>Drug Dev. Res.</source><volume>81</volume><year>2020</year><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1002/ddr.21656</pub-id><pub-id pub-id-type="pmid">32129518</pub-id><pub-id pub-id-type="pmcid">PMC7228359</pub-id></element-citation></ref><ref id="bib132"><label>132</label><mixed-citation publication-type="other" id="sref132">NIH-Clinicaltrialsgov. Losartan for patients with COVID-19 requiring hospitalization<italic toggle="yes">.</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04312009" id="intref0120">https://clinicaltrialsgov/ct2/show/NCT04312009</ext-link> Accessed on 30 June 2020.</mixed-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="other" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>Camostat mesylate in COVID-19 outpatients</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04353284" id="intref0125">https://clinicaltrialsgov/ct2/show/NCT04353284</ext-link><comment>Accessed on</comment></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Salata</surname><given-names>C.</given-names></name><name name-style="western"><surname>Munegato</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martelli</surname></name></person-group><article-title>Amiodarone affects Ebola virus binding and entry into target cells</article-title><source>New Microbiol.</source><volume>41</volume><year>2018</year><fpage>162</fpage><lpage>164</lpage><comment>PMID: 29498743</comment><pub-id pub-id-type="pmid">29498743</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="other" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>Amiodarone or verapamil in COVID-19 hospitalized patients with symptoms</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04351763" id="intref0130">https://clinicaltrialsgov/ct2/show/NCT04351763</ext-link><comment>Accessed on</comment></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Neutralizing antibodies for the treatment of COVID-19</article-title><source>Nat Biomed Eng</source><volume>4</volume><year>2020</year><fpage>1134</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00660-2</pub-id><pub-id pub-id-type="pmid">33293725</pub-id><pub-id pub-id-type="pmcid">PMC7891858</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="other" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>ACTIV-3: therapeutics for inpatients with COVID-19 (TICO)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04501978" id="intref0135">https://clinicaltrials.gov/ct2/show/NCT04501978</ext-link><comment>Accessed on</comment></element-citation></ref><ref id="bib138"><label>138</label><mixed-citation publication-type="other" id="sref138">NIH-Clinicaltrialsgov. ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04501978" id="intref0140">https://clinicaltrials.gov/ct2/show/NCT04501978</ext-link>. Accessed on 10 January 2020.</mixed-citation></ref><ref id="bib139"><label>139</label><mixed-citation publication-type="other" id="sref139">NIH-Clinicaltrialsgov. Multisite adaptive trials for Covid-19. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04370262" id="intref0145">https://clinicaltrialsgov/ct2/show/NCT04370262</ext-link> Accessed on 30 June 2020.</mixed-citation></ref><ref id="bib140"><label>140</label><mixed-citation publication-type="other" id="sref140">NIH-Clinicaltrialsgov. Umifenovir in Hospitalized COVID-19 patients <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04350684" id="intref0150">https://clinicaltrialsgov/ct2/show/NCT04350684</ext-link> Accessed on 30 June 2020.</mixed-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>D.C.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ji</surname><given-names>H.-F.</given-names></name></person-group><article-title>A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease</article-title><source>Trav. Med. Infect. Dis.</source><volume>35</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101646</pub-id><comment>101646&#8211;101646</comment><pub-id pub-id-type="pmcid">PMC7152904</pub-id><pub-id pub-id-type="pmid">32294562</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmid">32423584</pub-id><pub-id pub-id-type="pmcid">PMC7190303</pub-id></element-citation></ref><ref id="bib143"><label>143</label><mixed-citation publication-type="other" id="sref143">WHO. Coronavirus disease (COVID-19) recommendation: Avaialble from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients" id="intref0155">https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients</ext-link> . Accessed November 2020.</mixed-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Fantini</surname><given-names>J.</given-names></name><name name-style="western"><surname>di Scala</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chahinian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yahi</surname><given-names>N.</given-names></name></person-group><article-title>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title><source>Int. J. Antimicrob. Agents</source><volume>5</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105960</pub-id><pub-id pub-id-type="pmcid">PMC7128678</pub-id><pub-id pub-id-type="pmid">32251731</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Neher</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dyrdak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Druelle</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hodcroft</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>J.</given-names></name></person-group><article-title>Potential impact of seasonal forcing on a SARS-CoV-2 pandemic</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.13.20022806</pub-id><comment>2002.2013.20022806</comment><pub-id pub-id-type="pmid">32176808</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name></person-group><article-title>Progress and prospects on vaccine development against SARS-CoV-2</article-title><source>Vaccines</source><volume>8</volume><year>2020</year><fpage>153</fpage><pub-id pub-id-type="pmid">32235387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8020153</pub-id><pub-id pub-id-type="pmcid">PMC7349596</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.-G.</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id><pub-id pub-id-type="pmcid">PMC7094943</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="book" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Harcourt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kamili</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakthivel</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Queen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Paden</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>C.</given-names></name><etal/></person-group><part-title>Isolation and Characterization of SARS-CoV-2 from the First US COVID-19 Patient, bioRxiv: the Preprint Server for Biology</part-title><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.02.972935</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name></person-group><article-title>The challenges of vaccine development against a new virus during a pandemic</article-title><source>Cell Host Microbe</source><volume>27</volume><year>2020</year><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.021</pub-id><pub-id pub-id-type="pmid">32407708</pub-id><pub-id pub-id-type="pmcid">PMC7219397</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</article-title><source>bioRxiv</source><year>2020</year><fpage>939389</fpage><pub-id pub-id-type="doi">10.1101/2020.02.07.939389</pub-id><comment>2002.2007</comment><pub-id pub-id-type="pmid">32380511</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name></person-group><article-title>Animal models for emerging coronavirus: progress and new insights</article-title><source>Emerg. Microb. Infect.</source><volume>9</volume><year>2020</year><fpage>949</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1764871</pub-id><pub-id pub-id-type="pmcid">PMC7269044</pub-id><pub-id pub-id-type="pmid">32378471</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuwahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates</article-title><source>ACS Infect. Dis.</source><volume>2</volume><year>2016</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id><pub-id pub-id-type="pmid">27627203</pub-id><pub-id pub-id-type="pmcid">PMC7075522</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Padron-Regalado</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for SARS-CoV-2: lessons from other coronavirus strains</article-title><source>Infect. Dis. Ther.</source><volume>9</volume><year>2020</year><fpage>255</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/s40121-020-00300-x</pub-id><pub-id pub-id-type="pmid">32328406</pub-id><pub-id pub-id-type="pmcid">PMC7177048</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Nechipurenko</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Anashkina</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Matveeva</surname><given-names>O.V.</given-names></name></person-group><article-title>Change of antigenic determinants of SARS-CoV-2 virus S-protein as a possible cause of antibody-dependent enhancement of virus infection and cytokine storm</article-title><source>Biophysics</source><volume>65</volume><year>2020</year><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1134/S0006350920040119</pub-id><pub-id pub-id-type="pmid">33100352</pub-id><pub-id pub-id-type="pmcid">PMC7569100</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Sbrana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Atmar</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PloS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e35421</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id><pub-id pub-id-type="pmid">22536382</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Weingartl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Czub</surname><given-names>M.</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marszal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gren</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>12672</fpage><lpage>12676</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.22.12672-12676.2004</pub-id><pub-id pub-id-type="pmid">15507655</pub-id><pub-id pub-id-type="pmcid">PMC525089</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Amanat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines: status report</article-title><source>Immunity</source><volume>52</volume><year>2020</year><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id><pub-id pub-id-type="pmid">32259480</pub-id><pub-id pub-id-type="pmcid">PMC7136867</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Thanh Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Andreadakis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rom&#225;n</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Tollefsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The COVID-19 vaccine development landscape</article-title><source>Nat. Rev. Drug Discov.</source><volume>19</volume><year>2020</year><fpage>305</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><pub-id pub-id-type="pmid">32273591</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="other" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>WHO</surname></name></person-group><article-title>DRAFT landscape of COVID-19 candidate vaccines</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="intref0160">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link><comment>accessed on</comment></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="book" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Food and Drug Administration</surname></name></person-group><part-title>COVID-19 Vaccine Emergency Use Authorization. Silver Spring</part-title><year>2020</year><publisher-name>US Department of Health and Human Services, Food and Drug Administration</publisher-name><publisher-loc>MD</publisher-loc><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines" id="intref0165">https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines</ext-link></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>X.</given-names></name></person-group><article-title>The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines</article-title><source>NPJ vaccines</source><volume>5</volume><year>2020</year><pub-id pub-id-type="doi">10.1038/s41541-020-0170-0</pub-id><comment>18-18</comment><pub-id pub-id-type="pmcid">PMC7060195</pub-id><pub-id pub-id-type="pmid">32194995</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><year>2020</year><object-id pub-id-type="publisher-id">eabc1932</object-id><pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 -59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>30843</fpage><lpage>30844</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id><pub-id pub-id-type="pmid">33217362</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="other" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>Clinical trial of efficacy and safety of Sinovac's adsorbed COVID-19 (inactivated) vaccine in healthcare professionals (PROFISCOV)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&amp;cond=covid-19&amp;draw=2.%202020a" id="intref0170">https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&amp;cond=covid-19&amp;draw=2. 2020a</ext-link></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="other" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>ChiCTR</surname></name></person-group><article-title>Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://wwwchictrorgcn/showprojenaspx?proj=52227%202020a" id="intref0175">http://wwwchictrorgcn/showprojenaspx?proj=52227 2020a</ext-link></element-citation></ref><ref id="bib167"><label>167</label><mixed-citation publication-type="other" id="sref167">ChiCTR. Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=56651.%202020b" id="intref0180">http://www.chictr.org.cn/showprojen.aspx?proj=56651. 2020b</ext-link>.</mixed-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="other" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>Efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy adult population in Peru (cov-Peru)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04612972" id="intref0185">https://clinicaltrials.gov/ct2/show/NCT04612972</ext-link></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Roper</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>K.E.</given-names></name></person-group><article-title>SARS vaccines: where are we?</article-title><source>Expert Rev. Vaccines</source><volume>8</volume><year>2009</year><fpage>887</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1586/erv.09.43</pub-id><pub-id pub-id-type="pmid">19538115</pub-id><pub-id pub-id-type="pmcid">PMC7105754</pub-id></element-citation></ref><ref id="bib170"><label>170</label><mixed-citation publication-type="other" id="sref170">NIH-Clinicaltrialsgov Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04368988?term=vaccine&amp;recrs=a&amp;cond=covid-19&amp;draw=2" id="intref0190">https://clinicaltrialsgov/ct2/show/NCT04368988?term=vaccine&amp;recrs=a&amp;cond=covid-19&amp;draw=2</ext-link> Accessed on 18 June 2020c.</mixed-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="other" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>NIH-Clinicaltrialsgov</surname></name></person-group><article-title>A study looking at the efficacy, immune response, and safety of a COVID-19 vaccine in adults at risk for SARS-CoV 2</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04611802?term=NCT04611802&amp;draw=2&amp;rank=1" id="intref0195">https://clinicaltrials.gov/ct2/show/NCT04611802?term=NCT04611802&amp;draw=2&amp;rank=1</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04583995" id="intref0200">https://clinicaltrials.gov/ct2/show/NCT04583995</ext-link></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Ghorbani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sazegari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Afsharifar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>M.H.</given-names></name></person-group><article-title>A. Pormohammad Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach</article-title><source>New Microbes and New Infections</source><volume>38</volume><year>2020</year><fpage>100786</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2020.100786</pub-id><pub-id pub-id-type="pmid">33072338</pub-id><pub-id pub-id-type="pmcid">PMC7556220</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="book" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Business Wire</surname></name></person-group><part-title>Medicago Announces Positive Results in Animal Trials for its Vaccine Candidate against COVID-19. STT</part-title><year>2020</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sttinfo.fi/tiedote/medicago-announces-positive-results-in-animal-trialsfor-its-vaccine-candidate-against-covid-19?publisherId%20=58763726&amp;releaseId=69881188" id="intref0205">https://www.sttinfo.fi/tiedote/medicago-announces-positive-results-in-animal-trialsfor-its-vaccine-candidate-against-covid-19?publisherId =58763726&amp;releaseId=69881188</ext-link></element-citation></ref><ref id="bib174"><label>174</label><mixed-citation publication-type="other" id="sref174">NIH-Clinicaltrialsgov. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04636697" id="intref0210">https://clinicaltrials.gov/ct2/show/NCT04636697</ext-link>.</mixed-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines - a new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><volume>17</volume><year>2018</year><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="book" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pande</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Upreti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samant</surname><given-names>M.</given-names></name></person-group><part-title>Vaccination strategies to combat novel corona virus SARS-CoV-2</part-title><year>2020</year><publisher-name>Life Sci</publisher-name><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117956</pub-id><comment>117956</comment><pub-id pub-id-type="pmcid">PMC7289747</pub-id><pub-id pub-id-type="pmid">32535078</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kream</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>G.B.</given-names></name></person-group><article-title>An evidence based perspective on mRNA-SARS-CoV-2 vaccine development</article-title><source>Med. Sci. Mon.: Int. Med. J. Exp. Clin. Res.</source><volume>26</volume><year>2020</year><pub-id pub-id-type="doi">10.12659/MSM.924700</pub-id><comment>e924700-e924700</comment><pub-id pub-id-type="pmcid">PMC7218962</pub-id><pub-id pub-id-type="pmid">32366816</pub-id></element-citation></ref><ref id="bib178"><label>178</label><mixed-citation publication-type="other" id="sref178">NIH-Clinicaltrialsgov. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04283461?term=vaccine&amp;cond=covid-19&amp;draw=2" id="intref0215">https://clinicaltrialsgov/ct2/show/NCT04283461?term=vaccine&amp;cond=covid-19&amp;draw=2</ext-link> Accessed on 18 June 2020d.</mixed-citation></ref><ref id="bib179"><label>179</label><mixed-citation publication-type="other" id="sref179">NIH-Clinicaltrialsgov. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&amp;cond=covid-19&amp;draw=5" id="intref0220">https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&amp;cond=covid-19&amp;draw=5</ext-link> Accessed on 16 August. 2020e.</mixed-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>olack</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koury</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Hammitt</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>O.</given-names></name></person-group><article-title>C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA covid-19, vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name></person-group><article-title>Comparison of plasmid DNA and mRNA as vaccine technologies</article-title><source>Vaccines</source><volume>7</volume><year>2019</year><fpage>37</fpage><pub-id pub-id-type="pmid">31022829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7020037</pub-id><pub-id pub-id-type="pmcid">PMC6631684</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tursi</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>Harnessing recent advances in synthetic DNA and electroporation technologies for rapid vaccine development against COVID-19 and other emerging infectious diseases</article-title><source>Frontiers in Medical Technology</source><volume>2</volume><year>2020</year><pub-id pub-id-type="doi">10.3389/fmedt.2020.571030</pub-id><pub-id pub-id-type="pmcid">PMC8757735</pub-id><pub-id pub-id-type="pmid">35047878</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.R.F.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>2601</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="other" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>ClinicalTrialsgov</surname></name></person-group><article-title>Safety, immunogenicity, and efficacy of INO-4800 for COVID-19 in healthy seronegative adults at high risk of SARS-CoV-2 exposure</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04642638" id="intref0225">https://clinicaltrials.gov/ct2/show/NCT04642638</ext-link></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Nuismer</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Antia R</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant vector vaccine evolution</article-title><source>PLoS Comput. Biol.</source><volume>15</volume><year>2019</year><object-id pub-id-type="publisher-id">e1006857</object-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006857</pub-id><pub-id pub-id-type="pmcid">PMC6668849</pub-id><pub-id pub-id-type="pmid">31323032</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group><article-title>Developments in viral vector-based vaccines</article-title><source>Vaccines</source><volume>2</volume><year>2014</year><fpage>624</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Port</surname><given-names>J.R.</given-names><suffix>.</suffix></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>bioRxiv</source><year>2020</year><object-id pub-id-type="publisher-id">093195</object-id><pub-id pub-id-type="doi">10.1101/2020.05.13.093195</pub-id><comment>2005.2013</comment><pub-id pub-id-type="pmid">33469217</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="other" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>EU</surname><given-names>C.T.R.</given-names></name></person-group><article-title>A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwclinicaltrialsregistereu/ctr-search/trial/2020-001228-32/GB" id="intref0230">https://wwwclinicaltrialsregistereu/ctr-search/trial/2020-001228-32/GB</ext-link><comment>Accessed on</comment></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.-C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-X.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.-C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.-F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-J.</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="book" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>ChiCTR</surname><given-names>A.</given-names></name></person-group><part-title>Phase II Clinical Trial of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) Chictr</part-title><year>2020</year><comment>org.cn/showproj.aspx?proj=63754</comment></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Fierros</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garc&#237;a-Silva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name></person-group><article-title>Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?</article-title><source>Expet Opin. Biol. Ther.</source><volume>20</volume><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/14712598.2020.1767062</pub-id><pub-id pub-id-type="pmid">32380868</pub-id></element-citation></ref><ref id="bib193"><label>193</label><mixed-citation publication-type="other" id="sref193">NIH-Clinicaltrialsgov. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrialsgov/ct2/show/NCT04327206" id="intref0235">https://clinicaltrialsgov/ct2/show/NCT04327206</ext-link> Accessed on 16 June 2020.</mixed-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Hensel</surname><given-names>J.</given-names></name><name name-style="western"><surname>McAndrews</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McGrail</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses</article-title><source>Sci. Rep.</source><volume>10</volume><year>2020</year><fpage>18377</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-75491-x</pub-id><pub-id pub-id-type="pmid">33110184</pub-id><pub-id pub-id-type="pmcid">PMC7591473</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>